Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 653 articles:
HTML format



Single Articles


    June 2020
  1. ABUFARAJ M, Iwata T, Kimura S, Haddad A, et al
    Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
    Eur Urol. 2020 Jun 27. pii: S0302-2838(20)30429.
    PubMed     Abstract available


  2. CHIN JL, Bauman GS
    Re: Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Eur Urol. 2020 Jun 27. pii: S0302-2838(20)30445.
    PubMed    


  3. TROYER D
    High-risk Prostate Cancer Patients Are Not All Alike.
    Eur Urol. 2020 Jun 27. pii: S0302-2838(20)30453.
    PubMed    


  4. BROOKMAN-MAY SD, May M
    Re: Androgen-deprivation Therapies for Prostate Cancer and Risk of Infection by SARS-CoV-2: A Population-based Study (n=4532).
    Eur Urol. 2020 Jun 16. pii: S0302-2838(20)30443.
    PubMed    


  5. MUKHERJI D, Omlin A, Pezaro C
    Living Longer and Better with Advanced Prostate Cancer.
    Eur Urol. 2020 Jun 15. pii: S0302-2838(20)30360.
    PubMed    


  6. PADHANI AR, Villeirs G, Ahmed HU, Panebianco V, et al
    Platinum Opinion Counterview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound.
    Eur Urol. 2020 Jun 12. pii: S0302-2838(20)30416.
    PubMed    


  7. MORIS L, Mottet N, Wiegel T
    Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostat
    Eur Urol. 2020 Jun 11. pii: S0302-2838(20)30414.
    PubMed    


  8. GREGUCCI F, Carbonara R, Fiorentino A
    Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Eur Urol. 2020 Jun 10. pii: S0302-2838(20)30412.
    PubMed    


  9. NYBERG T, Frost D, Barrowdale D, Evans DG, et al
    Prostate Cancer Risk by BRCA2 Genomic Regions.
    Eur Urol. 2020 Jun 10. pii: S0302-2838(20)30345.
    PubMed     Abstract available


  10. ARMSTRONG AJ, Lin P, Tombal B, Saad F, et al
    Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
    Eur Urol. 2020 Jun 9. pii: S0302-2838(20)30329.
    PubMed     Abstract available


  11. LEBASTCHI AH, George AK, Polascik TJ, Coleman J, et al
    Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
    Eur Urol. 2020 Jun 9. pii: S0302-2838(20)30358.
    PubMed     Abstract available


  12. LAVORGNA G, Montorsi F, Salonia A
    Re: Hung-Ming Lam, Holly M. Nguyen, Mark P. Labrecque, et al. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcrip
    Eur Urol. 2020 Jun 8. pii: S0302-2838(20)30363.
    PubMed    


  13. SIMPSON BS, Carmona Echeverria LM, Norris JM, Ahmed HU, et al
    Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol 2020;77:501-7.
    Eur Urol. 2020 Jun 8. pii: S0302-2838(20)30342.
    PubMed    


  14. CHESNUT GT, Vickers AJ, Ehdaie B
    Reply to Benjamin S. Simpson, Lina M. Carmona Echeverria, Joseph M. Norris, Hashim U. Ahmed, Caroline M. Moore, and Hayley C. Whitaker's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnet
    Eur Urol. 2020 Jun 7. pii: S0302-2838(20)30355.
    PubMed    


    May 2020
  15. FETTKE H, Kwan EM, Docanto MM, Bukczynska P, et al
    Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
    Eur Urol. 2020 May 30. pii: S0302-2838(20)30219.
    PubMed     Abstract available


  16. KISHAN AU, Romero T, Alshalalfa M, Liu Y, et al
    Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer.
    Eur Urol. 2020 May 24. pii: S0302-2838(20)30349.
    PubMed     Abstract available


  17. MONDA SM, Dall'Era MA
    What Are We Missing? Magnetic Resonance Imaging-negative Clinically Significant Prostate Cancer in PROMIS.
    Eur Urol. 2020 May 22. pii: S0302-2838(20)30351.
    PubMed    


  18. HERBERTS C, Murtha AJ, Fu S, Wang G, et al
    Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2020 May 22. pii: S0302-2838(20)30326.
    PubMed     Abstract available


  19. SATHIANATHEN NJ, Omer A, Harriss E, Davies L, et al
    Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.
    Eur Urol. 2020 May 20. pii: S0302-2838(20)30223.
    PubMed     Abstract available


  20. MAI Z, Yuan R
    Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathan I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
    Eur Urol. 2020 May 19. pii: S0302-2838(20)30337.
    PubMed    


  21. STABILE A, Orczyk C, Giganti F, Moschini M, et al
    The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series.
    Eur Urol. 2020 May 19. pii: S0302-2838(20)30336.
    PubMed     Abstract available


  22. DARST BF, Wan P, Sheng X, Bensen JT, et al
    A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.
    Eur Urol. 2020 May 11. pii: S0302-2838(20)30328.
    PubMed     Abstract available


  23. LA TAILLE A, Ingels A
    Re: Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.
    Eur Urol. 2020 May 10. pii: S0302-2838(20)30244.
    PubMed    


  24. VICKERS A, Carlsson SV, Cooperberg M
    Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence.
    Eur Urol. 2020 May 7. pii: S0302-2838(20)30248.
    PubMed     Abstract available


  25. WALZ J
    Re: Prostate-specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2020 May 7. pii: S0302-2838(20)30237.
    PubMed    


  26. ZLOTTA AR, Sadeghian A
    Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-based, Diagnostic Study.
    Eur Urol. 2020 May 7. pii: S0302-2838(20)30242.
    PubMed    


  27. VILLERS A, Olivier J
    Re: Long-term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience.
    Eur Urol. 2020 May 7. pii: S0302-2838(20)30235.
    PubMed    


  28. RODRIGUEZ SANCHEZ L, Macek P, Barbe Y, Cathelineau X, et al
    Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
    Eur Urol. 2020 May 6. pii: S0302-2838(20)30254.
    PubMed    


  29. CHESNUT GT, Vertosick EA, Ehdaie B
    Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men
    Eur Urol. 2020 May 5. pii: S0302-2838(20)30318.
    PubMed    


  30. ZELIC R, Garmo H, Zugna D, Stattin P, et al
    Corrigendum re "Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study" [Eur Urol 2020;77:180-8].
    Eur Urol. 2020 May 5. pii: S0302-2838(20)30191.
    PubMed    


  31. MARCISCANO AE, Barbieri CE
    CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?
    Eur Urol. 2020 May 4. pii: S0302-2838(20)30239.
    PubMed    


  32. RADTKE JP, Hadaschik B
    Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
    Eur Urol. 2020 May 4. pii: S0302-2838(20)30246.
    PubMed    


  33. FROEHNER M, Koch R, Thomas C
    Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
    Eur Urol. 2020 May 4. pii: S0302-2838(20)30151.
    PubMed    


  34. KANAYAMA M, Luo J
    Predictive Biomarkers in Prostate Cancer: Is It Time To Go "All In" on Liquid Biopsies?
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30321.
    PubMed    


  35. ALBERTSEN PC
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30249.
    PubMed    


  36. NORRIS JM, Carmona Echeverria LM, Bott SRJ, Brown LC, et al
    What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort.
    Eur Urol. 2020 May 1. pii: S0302-2838(20)30261.
    PubMed     Abstract available


  37. HADASCHIK B, Herrmann K
    Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study.
    Eur Urol. 2020 May 1. pii: S0302-2838(20)30319.
    PubMed    


    April 2020
  38. DU J, Liu Y, Yan W
    Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://d
    Eur Urol. 2020 Apr 30. pii: S0302-2838(20)30245.
    PubMed    


  39. STAVRINIDES V, Giganti F, Trock B, Punwani S, et al
    Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
    Eur Urol. 2020 Apr 29. pii: S0302-2838(20)30210.
    PubMed     Abstract available


  40. SACHDEV S, Zhang H, Hussain M
    Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer.
    Eur Urol. 2020 Apr 25. pii: S0302-2838(20)30228.
    PubMed    


  41. STENZL A, Dunshee C, De Giorgi U, Alekseev B, et al
    Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
    Eur Urol. 2020 Apr 23. pii: S0302-2838(20)30194.
    PubMed     Abstract available


  42. MOSCHOVAS MC, Sighinolfi MC, Rocco B, Bhat S, et al
    Balancing the Effects of COVID-19 Against Potential Progression and Mortality in High-risk Prostate Cancer.
    Eur Urol. 2020 Apr 21. pii: S0302-2838(20)30260.
    PubMed    


  43. MATTEI A, Wurnschimmel C, Baumeister P, Hyseni A, et al
    Standardized and Simplified Robot-assisted Superextended Pelvic Lymph Node Dissection for Prostate Cancer: The Monoblock Technique.
    Eur Urol. 2020 Apr 20. pii: S0302-2838(20)30207.
    PubMed     Abstract available


  44. WILT TJ, Dahm P, Brawer MK
    Reply to Roderick C.N. van den Bergh, Massimo Valerio, Derya Tilki, and Giorgio Gandaglia's Letter to the Editor re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Ext
    Eur Urol. 2020 Apr 14. pii: S0302-2838(20)30222.
    PubMed    


  45. VAN DEN BERGH RCN, Valerio M, Tilki D, Gandaglia G, et al
    Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. https:/
    Eur Urol. 2020 Apr 14. pii: S0302-2838(20)30221.
    PubMed    


  46. HESS BA JR
    Re: Nobuaki Matsubara, Kim N. Chi, Mustafa Ozguroglu, et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone
    Eur Urol. 2020 Apr 11. pii: S0302-2838(20)30193.
    PubMed    


  47. COOPERBERG MR, Lin DW
    Active Surveillance for Prostate Cancer: A 2020 Vision.
    Eur Urol. 2020 Apr 10. pii: S0302-2838(20)30152.
    PubMed    


  48. DEARNALEY DP, Saltzstein DR, Sylvester JE, Karsh L, et al
    The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-g
    Eur Urol. 2020 Apr 6. pii: S0302-2838(20)30142.
    PubMed     Abstract available


  49. CARLSSON SV, Eastham JA, Crawford ED, Harris RG, et al
    "PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older.
    Eur Urol. 2020 Apr 6. pii: S0302-2838(20)30203.
    PubMed     Abstract available


  50. GANDAGLIA G, Martini A, Ploussard G, Fossati N, et al
    External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection.
    Eur Urol. 2020 Apr 5. pii: S0302-2838(20)30198.
    PubMed     Abstract available


    March 2020
  51. VON EYBEN FE, Bauman G, Soydal C, Paganelli G, et al
    Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508-47 https://doi.org/10.1016/j.eururo.2020.01.012
    Eur Urol. 2020 Mar 25. pii: S0302-2838(20)30153.
    PubMed    


  52. MORI K, Egawa S, Shariat SF
    Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    Eur Urol. 2020 Mar 21. pii: S0302-2838(20)30130.
    PubMed    


  53. ALBERTSEN PC
    William Halsted and Prostate Cancer Progression.
    Eur Urol. 2020 Mar 21. pii: S0302-2838(20)30148.
    PubMed    


  54. LLORENTE C
    Re: Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.
    Eur Urol. 2020 Mar 12. pii: S0302-2838(20)30140.
    PubMed    


  55. VAN DER POEL HG
    Re: Apalutamide and Overall Survival in Non-metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2020 Mar 12. pii: S0302-2838(20)30125.
    PubMed    


  56. WIRTH M, Stief C, Stenzl A
    Re: Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy Versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness.
    Eur Urol. 2020 Mar 9. pii: S0302-2838(20)30133.
    PubMed    


  57. SKOLARIKOS A
    Re: Effects of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Study.
    Eur Urol. 2020 Mar 5. pii: S0302-2838(20)30134.
    PubMed    


  58. MORIS L, Cumberbatch MG, Van den Broeck T, Gandaglia G, et al
    Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Eur Urol. 2020 Mar 4. pii: S0302-2838(20)30071.
    PubMed     Abstract available


  59. LORENTE D, Castro E, Lozano R, Puente J, et al
    Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2020 Mar 3. pii: S0302-2838(20)30135.
    PubMed    


    February 2020
  60. PHILIPPOU Y, Protheroe AS, Bryant RJ
    Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study.
    Eur Urol. 2020 Feb 27. pii: S0302-2838(20)30136.
    PubMed    


  61. VILASECA A, Ribal MJ
    Re: Detection and Localisation of Primary Prostate Cancer Using (68)Ga-PSMA PET/CT Compared with mpMRI and Radical Prostatectomy Specimens.
    Eur Urol. 2020 Feb 27. pii: S0302-2838(20)30127.
    PubMed    


  62. MONTORSI F, Gandaglia G, Fossati N, Salonia A, et al
    Re: Ola Bratt, Erik Holmberg, Ove Andren, et al. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Swed
    Eur Urol. 2020 Feb 25. pii: S0302-2838(20)30059.
    PubMed    


  63. LOEB S, Byrne NK, Wang B, Makarov DV, et al
    Exploring Variation in the Use of Conservative Management for Low-risk Prostate Cancer in the Veterans Affairs Healthcare System.
    Eur Urol. 2020 Feb 22. pii: S0302-2838(20)30101.
    PubMed     Abstract available


  64. MOROTE J, Celma A, Planas J
    Re: Frank-Jan H. Drost, Daniel Osses, Daan Nieboer, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-anal
    Eur Urol. 2020 Feb 20. pii: S0302-2838(20)30116.
    PubMed    


  65. WILT TJ, Vo TN, Langsetmo L, Dahm P, et al
    Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).
    Eur Urol. 2020 Feb 20. pii: S0302-2838(20)30115.
    PubMed     Abstract available


  66. CIMADAMORE A, Scarpelli M, Cheng L, Lopez-Beltran A, et al
    Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871.
    Eur Urol. 2020 Feb 20. pii: S0302-2838(20)30102.
    PubMed    


  67. SIGHINOLFI MC, Rocco B
    Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al's Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uro
    Eur Urol. 2020 Feb 14. pii: S0302-2838(20)30103.
    PubMed    


  68. BELTRAN H, Morris MJ
    Docetaxel for Early Prostate Cancer: What Have We Learned?
    Eur Urol. 2020 Feb 6. pii: S0302-2838(20)30064.
    PubMed    


  69. MONTORSI F, Fossati N, Gandaglia G, Briganti A, et al
    Re: Aurelie De Bruycker, Elise De Bleser, Karel Decaestecker, et al. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. Eur Urol 2019;75:826-33: N
    Eur Urol. 2020 Feb 6. pii: S0302-2838(20)30068.
    PubMed    


  70. DAVIS JW
    Re: Medium-term Oncologic Outcomes in a Large Cohort of Men Treated with Focal or Hemi-ablation Using High-intensity Focused Ultrasonography for Primary Localized Prostate Cancer.
    Eur Urol. 2020 Feb 4. pii: S0302-2838(20)30067.
    PubMed    


  71. RUBIO-BRIONES J
    Re:Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    Eur Urol. 2020 Feb 3. pii: S0302-2838(20)30054.
    PubMed    


    January 2020
  72. GILLESSEN S, Attard G, Beer TM, Beltran H, et al
    Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
    Eur Urol. 2020 Jan 27. pii: S0302-2838(20)30048.
    PubMed     Abstract available


  73. ABREU AL
    The Pillars for Sustained Growth of Magnetic Resonance Imaging Pathway for Prostate Cancer Diagnosis: Quality, Reproducibility, Accessibility, Cost Effectiveness, and Training.
    Eur Urol. 2020 Jan 22. pii: S0302-2838(20)30004.
    PubMed    


  74. KIM JH, Jeong IG
    Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2019;76:284-303: Threshold Indi
    Eur Urol. 2020 Jan 21. pii: S0302-2838(20)30052.
    PubMed    


  75. HUNT TC, O'Neil BB
    Leveraging Behavioral Economics to Reduce Low-value Prostate Cancer Screening.
    Eur Urol. 2020 Jan 17. pii: S0302-2838(20)30001.
    PubMed     Abstract available


  76. CHIN J, Bauman G, Power N, Ward A, et al
    The Singularity is Near(ish): Emerging Applications of Artificial Intelligence in Prostate Cancer Management.
    Eur Urol. 2020 Jan 8. pii: S0302-2838(19)30945.
    PubMed    


  77. LIN DW, Shih MC, Aronson W, Basler J, et al
    Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study.
    Eur Urol. 2020 Jan 7. pii: S0302-2838(19)30964.
    PubMed     Abstract available


  78. TOSOIAN JJ, Mamawala M, Epstein JI, Landis P, et al
    Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
    Eur Urol. 2020 Jan 6. pii: S0302-2838(19)30961.
    PubMed     Abstract available


  79. FROEHNER M, Koch R, Thomas C
    Re: Giorgio Gandaglia G, Peter Albers, Per-Anders Abrahamsson, et al. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. Eur Urol 2019;76:142-50.
    Eur Urol. 2020;77:e30.
    PubMed    


    December 2019
  80. TODENHOFER T, Gratzke C
    Re: Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
    Eur Urol. 2019 Dec 21. pii: S0302-2838(19)30956.
    PubMed    


  81. CHESNUT GT, Vertosick EA, Benfante N, Sjoberg DD, et al
    Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.
    Eur Urol. 2019 Dec 21. pii: S0302-2838(19)30948.
    PubMed     Abstract available


  82. SLOVIN SF
    Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?
    Eur Urol. 2019 Dec 18. pii: S0302-2838(19)30910.
    PubMed    


  83. PATASIUS A, Smailyte G
    Re: MaryBeth B. Culp, Isabelle Soerjomataram, Jason A. Efstathiou, Freddie Bray, Ahmedin Jemal. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.08.005.
    Eur Urol. 2019 Dec 13. pii: S0302-2838(19)30908.
    PubMed    


  84. MATSUBARA N, Chi KN, Ozguroglu M, Rodriguez-Antolin A, et al
    Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Depriv
    Eur Urol. 2019 Dec 13. pii: S0302-2838(19)30894.
    PubMed     Abstract available


  85. LI YR, Roach M 3rd
    Re: Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
    Eur Urol. 2019 Dec 12. pii: S0302-2838(19)30900.
    PubMed    


  86. RADZISZEWSKI P, Szablonski W
    Re: Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Eur Urol. 2019 Dec 12. pii: S0302-2838(19)30902.
    PubMed    


  87. LEEST MV, Israel B, Engels RRM, Barentsz JO, et al
    Reply to Arnaldo Stanzione, Massimo Imbriaco, and Renato Cuocolo's Letter to the Editor re: Marloes van der Leest, Bas Israel, Eric Bastiaan Cornel, et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer D
    Eur Urol. 2019 Dec 6. pii: S0302-2838(19)30889.
    PubMed    


    November 2019
  88. VENDERINK W, Bomers JG, Overduin CG, Padhani AR, et al
    Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy.
    Eur Urol. 2019 Nov 29. pii: S0302-2838(19)30775.
    PubMed     Abstract available


  89. ALIBHAI SMH, Warde P
    Local Failure in High-grade Prostate Cancer: An Elusive but Important Outcome and Target for Clinical Trials.
    Eur Urol. 2019 Nov 28. pii: S0302-2838(19)30876.
    PubMed    


  90. STANZIONE A, Imbriaco M, Cuocolo R
    Re: Marloes van der Leest, Bas Israel, Eric Bastiaan Cornel, et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naive Men: The Next Step in Magnetic Resonance Imaging Accessibility.
    Eur Urol. 2019 Nov 28. pii: S0302-2838(19)30890.
    PubMed    


  91. KASIVISVANATHAN V, Giganti F, Emberton M, Moore CM, et al
    Magnetic Resonance Imaging Should Be Used in the Active Surveillance of Patients with Localised Prostate Cancer.
    Eur Urol. 2019 Nov 25. pii: S0302-2838(19)30886.
    PubMed    


  92. NEAL DE, Metcalfe C, Donovan JL, Lane JA, et al
    Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
    Eur Urol. 2019 Nov 23. pii: S0302-2838(19)30837.
    PubMed     Abstract available


  93. ISRAEL B, Leest MV, Sedelaar M, Padhani AR, et al
    Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation.
    Eur Urol. 2019 Nov 23. pii: S0302-2838(19)30823.
    PubMed     Abstract available


  94. DE BLESER E, Ost P
    Reply to Pirus Ghadjar, Thomas Wiegel's Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Compar
    Eur Urol. 2019 Nov 16. pii: S0302-2838(19)30842.
    PubMed    


  95. GHADJAR P, Wiegel T
    Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherap
    Eur Urol. 2019 Nov 16. pii: S0302-2838(19)30841.
    PubMed    


  96. PLOUSSARD G
    Re: Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Nov 11. pii: S0302-2838(19)30780.
    PubMed    


  97. KISHAN AU, Chu FI, King CR, Seiferheld W, et al
    Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.
    Eur Urol. 2019 Nov 9. pii: S0302-2838(19)30774.
    PubMed     Abstract available


  98. HERLEMANN A
    Pretreatment Risk Stratification Tools for Prostate Cancer-Moving from Good to Better, Toward the Best.
    Eur Urol. 2019 Nov 3. pii: S0302-2838(19)30782.
    PubMed    


  99. WANG X, Chen H, Luo J, Xie L, et al
    CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?
    Eur Urol. 2019 Nov 3. pii: S0302-2838(19)30781.
    PubMed    


    October 2019
  100. SATHIANATHEN NJ, Koschel S, Thangasamy IA, Teh J, et al
    Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Eur Urol. 2019 Oct 31. pii: S0302-2838(19)30693.
    PubMed     Abstract available


  101. KARZAI F, Madan RA, Dahut WL
    How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer?
    Eur Urol. 2019 Oct 29. pii: S0302-2838(19)30767.
    PubMed    


  102. GRAF RP, Hullings M, Barnett ES, Carbone E, et al
    Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Oct 21. pii: S0302-2838(19)30669.
    PubMed     Abstract available


  103. REIMERS MA, Yip SM, Zhang L, Cieslik M, et al
    Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
    Eur Urol. 2019 Oct 20. pii: S0302-2838(19)30764.
    PubMed     Abstract available


  104. TAN WP, Polascik TJ
    Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality Dess RT, Hartman HE, Mahal BA, et al JAMA Oncol 2019;5:975-83.
    Eur Urol. 2019 Oct 17. pii: S0302-2838(19)30686.
    PubMed    


  105. NYAME YA, Gore JL
    What Goes Up Must Come Down: Identifying Truth from Global Prostate Cancer Epidemiology.
    Eur Urol. 2019 Oct 16. pii: S0302-2838(19)30738.
    PubMed    


  106. MONTGOMERY B, Plymate S
    Clinical Acumen Versus Androgen Receptor Variant 7 Circulating Tumor Cells in Decision-Making for Men with Advanced Prostate Cancer.
    Eur Urol. 2019 Oct 12. pii: S0302-2838(19)30756.
    PubMed    


  107. MARRA G, Van Velthoven R, Valerio M
    Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Salvage Robotic Radical Prostatectomy
    Eur Urol. 2019 Oct 10. pii: S0302-2838(19)30759.
    PubMed    


  108. ZELIC R, Garmo H, Zugna D, Stattin P, et al
    Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.
    Eur Urol. 2019 Oct 9. pii: S0302-2838(19)30755.
    PubMed     Abstract available


  109. WEI Y, Zhang R, Ye L
    Re: Manfred Wirth, Nicola Fossati, Peter Albers, et al. The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. Eur Urol 2019;76:179-86.
    Eur Urol. 2019 Oct 5. pii: S0302-2838(19)30754.
    PubMed    


  110. THIERY-VUILLEMIN A, Hvid Poulsen M, Lagneau E, Ploussard G, et al
    Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    Eur Urol. 2019 Oct 5. pii: S0302-2838(19)30739.
    PubMed     Abstract available


  111. SWEENEY CJ, Beltran H
    The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data.
    Eur Urol. 2019 Oct 4. pii: S0302-2838(19)30737.
    PubMed    


  112. LAM TBL, MacLennan S, Willemse PM, Mason MD, et al
    EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study).
    Eur Urol. 2019 Oct 3. pii: S0302-2838(19)30740.
    PubMed     Abstract available


    September 2019
  113. ENGELS RRM, Israel B, Padhani AR, Barentsz JO, et al
    Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition.
    Eur Urol. 2019 Sep 30. pii: S0302-2838(19)30741.
    PubMed     Abstract available


  114. GANDAGLIA G, Ploussard G, Valerio M, Mattei A, et al
    The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prosta
    Eur Urol. 2019 Sep 21. pii: S0302-2838(19)30694.
    PubMed     Abstract available


  115. HUEBNER NA, Shariat SF
    Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2019 Sep 19. pii: S0302-2838(19)30679.
    PubMed    


  116. TAPLIN ME, Antonarakis ES, Ferrante KJ, Horgan K, et al
    Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Sep 18. pii: S0302-2838(19)30684.
    PubMed     Abstract available


  117. ALCARAZ A
    Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2019 Sep 12. pii: S0302-2838(19)30683.
    PubMed    


  118. NYBERG T, Frost D, Barrowdale D, Evans DG, et al
    Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Eur Urol. 2019 Sep 5. pii: S0302-2838(19)30675.
    PubMed     Abstract available


  119. CULP MB, Soerjomataram I, Efstathiou JA, Bray F, et al
    Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.
    Eur Urol. 2019 Sep 4. pii: S0302-2838(19)30619.
    PubMed     Abstract available


    August 2019
  120. DONG L, Pienta KJ
    Re: Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy of Clinically Localized, High Risk Prostate Cancer.
    Eur Urol. 2019 Aug 30. pii: S0302-2838(19)30678.
    PubMed    


  121. GORCHAKOV AA, Kulemzin SV, Kochneva GV, Taranin AV, et al
    Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Eur Urol. 2019 Aug 27. pii: S0302-2838(19)30658.
    PubMed     Abstract available


  122. DROST FH, Nieboer D, Morgan TM, Carroll PR, et al
    Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
    Eur Urol. 2019 Aug 23. pii: S0302-2838(19)30602.
    PubMed     Abstract available


  123. HOYLE AP, Ali A, James ND, Cook A, et al
    Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2019 Aug 22. pii: S0302-2838(19)30620.
    PubMed     Abstract available


  124. RAMNARINE VR, Kobelev M, Gibb EA, Nouri M, et al
    The evolution of long noncoding RNA acceptance in prostate cancer initiation and progression, and its clinical utility in disease management.
    Eur Urol. 2019 Aug 22. pii: S0302-2838(19)30601.
    PubMed     Abstract available


  125. KELLOKUMPU-LEHTINEN PL, Hjalm-Eriksson M, Thellenberg-Karlsson C, Astrom L, et al
    Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
    Eur Urol. 2019 Aug 20. pii: S0302-2838(19)30654.
    PubMed     Abstract available


  126. DONZELLI A, Castelluzzo G, Giudicatti G
    Re: Jonas Hugosson, Monique J. Roobol, Marianne Mansson, et al. A 16-yr Follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2019;76:43-51: Mortality in the Age Group >/=70yr and the Case of Italy.
    Eur Urol. 2019 Aug 20. pii: S0302-2838(19)30606.
    PubMed    


  127. VAN LEENDERS GJLH, Kweldam CF, Hollemans E, Kummerlin IP, et al
    Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    Eur Urol. 2019 Aug 19. pii: S0302-2838(19)30612.
    PubMed     Abstract available


  128. GLASER AW
    Resilience of men and the gap hypothesis of quality of life: Health utility outcome measurement in prostate cancer.
    Eur Urol. 2019 Aug 16. pii: S0302-2838(19)30607.
    PubMed    


  129. DESAI NB, Courtney K, Subramaniam RM, Cadeddu JA, et al
    Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer?
    Eur Urol. 2019 Aug 14. pii: S0302-2838(19)30611.
    PubMed    


  130. KETTUNEN K, Bostrom PJ, Taimen P
    Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30610.
    PubMed    


  131. KASIVISVANATHAN V, Takwoingi Y, Emberton M, Moore CM, et al
    Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti's Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostat
    Eur Urol. 2019 Aug 7. pii: S0302-2838(19)30604.
    PubMed    


  132. MONTORSI F, Gandaglia G, Briganti A
    Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review And Meta-analysis. Eur Urol. In press. https://doi.org/10.1
    Eur Urol. 2019 Aug 7. pii: S0302-2838(19)30603.
    PubMed    


  133. LU-YAO G, Nikita N, Keith SW, Nightingale G, et al
    Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
    Eur Urol. 2019 Aug 2. pii: S0302-2838(19)30585.
    PubMed     Abstract available


    July 2019
  134. THOMAS L, Baratchian M, Sharifi N
    Supraphysiologic Testosterone Solutions for Enzalutamide-resistant Prostate Cancer.
    Eur Urol. 2019 Jul 31. pii: S0302-2838(19)30596.
    PubMed    


  135. VAN DER POEL H
    Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.
    Eur Urol. 2019 Jul 26. pii: S0302-2838(19)30545.
    PubMed    


  136. BUTCHER G, Howard H, Sathianathen N, Catto JWF, et al
    Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2019 Jul 25. pii: S0302-2838(19)30542.
    PubMed    


  137. MCLENNAN D, Sathianathen N, Alghazo O, Azad A, et al
    Re: PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Jul 25. pii: S0302-2838(19)30550.
    PubMed    


  138. HOFMAN MS, Emmett L
    Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?
    Eur Urol. 2019 Jul 24. pii: S0302-2838(19)30584.
    PubMed    


  139. SIGHINOLFI MC, Rocco B
    Re: EAU Guidelines: Prostate Cancer 2019.
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30538.
    PubMed    


  140. STENZL A
    Re: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30549.
    PubMed    


  141. JEONG CW, Cowan JE, Broering JM, Ten Ham RMT, et al
    Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry.
    Eur Urol. 2019 Jul 22. pii: S0302-2838(19)30536.
    PubMed     Abstract available


  142. WALSH PC
    Re: Association of Treatment with 5alpha-Reductase inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    Eur Urol. 2019 Jul 22. pii: S0302-2838(19)30546.
    PubMed    


  143. DE BLESER E, Jereczek-Fossa BA, Pasquier D, Zilli T, et al
    Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
    Eur Urol. 2019 Jul 19. pii: S0302-2838(19)30533.
    PubMed     Abstract available


  144. CHEN S, Xiao Y, Wang X
    Re: Brandon A. Mahal, Mohammed Alshalalfa, Daniel E. Spratt, et al. Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. Eur Urol 2019;75:1038-40.
    Eur Urol. 2019 Jul 17. pii: S0302-2838(19)30529.
    PubMed    


  145. DROST FH, Osses D, Nieboer D, Bangma CH, et al
    Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.
    Eur Urol. 2019 Jul 17. pii: S0302-2838(19)30513.
    PubMed     Abstract available


  146. HACKMAN G, Taari K, Tammela TL, Matikainen M, et al
    Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.
    Eur Urol. 2019 Jul 17. pii: S0302-2838(19)30525.
    PubMed     Abstract available


  147. PASCHALIS A, Sheehan B, Riisnaes R, Rodrigues DN, et al
    Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
    Eur Urol. 2019 Jul 13. pii: S0302-2838(19)30520.
    PubMed     Abstract available


  148. LOGOTHETIS CJ, Aparicio A, Koinis F, Corn PG, et al
    Prostate Cancer: Quo Vadis?
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30521.
    PubMed     Abstract available


  149. PAL SK, Swami U, Agarwal N
    Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How.
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30519.
    PubMed    


  150. DE BRUYCKER A, Fonteyne V, Ost P
    Re: Gaetan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.016.
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30523.
    PubMed    


  151. VON EYBEN FE, Bauman G
    Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285-93.
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30516.
    PubMed    


  152. DIRIX PR, Dal Pra A, Wiegel T
    Re: Gaetan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.016.
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30524.
    PubMed    


    June 2019
  153. HOLSCHER T, Lohaus F, Wirth M, Troost EGC, et al
    Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zophel, Steffen Lock, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol
    Eur Urol. 2019 Jun 27. pii: S0302-2838(19)30506.
    PubMed    


  154. DIRIX PR, Mercier C, Dirix LY
    Re: Fabian Lohaus, Klaus Zophel, Steffen Lock, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
    Eur Urol. 2019 Jun 26. pii: S0302-2838(19)30507.
    PubMed    


  155. LIN X, Helfand BT, Xu J
    Re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al., Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol. In press. https://doi.org/10.1016/j.eur
    Eur Urol. 2019 Jun 24. pii: S0302-2838(19)30492.
    PubMed    


  156. WEI Y, Wu J, Gu W, Qin X, et al
    Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.
    Eur Urol. 2019 Jun 24. pii: S0302-2838(19)30453.
    PubMed     Abstract available


  157. RANASINGHE WKB, Reichard CA, Chapin BF
    Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
    Eur Urol. 2019 Jun 24. pii: S0302-2838(19)30499.
    PubMed     Abstract available


  158. KOTE-JARAI Z, Leongamornlert DA, Saunders EJ, Conti DV, et al
    Reply to Xiaoling Lin, Brian T. Helfand, and Jianfeng Xu's Letter to the Editor re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a
    Eur Urol. 2019 Jun 21. pii: S0302-2838(19)30491.
    PubMed    


  159. QIAN K, Ju L, Xiao Y
    Re: Stacy Loeb, Jacob Taylor, Mohit Butaney, et al. Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination. Eur Urol 2019;75:881-2.
    Eur Urol. 2019 Jun 19. pii: S0302-2838(19)30454.
    PubMed    


  160. LAM HM, Nguyen HM, Labrecque MP, Brown LG, et al
    Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.
    Eur Urol. 2019 Jun 18. pii: S0302-2838(19)30449.
    PubMed     Abstract available


  161. CLARKE N, Payne H, van der Meulen J
    Re: David W. Donnelly, Anna Gavin, Amy Downing, et al. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.018.
    Eur Urol. 2019 Jun 15. pii: S0302-2838(19)30450.
    PubMed    


  162. MONTIRONI R, Cheng L, Scarpelli M, Cimadamore A, et al
    Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?
    Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30442.
    PubMed    


  163. ISAACSSON VELHO P, Fu W, Wang H, Mirkheshti N, et al
    Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30439.
    PubMed     Abstract available


  164. EFSTATHIOU E, Davis JW, Pisters L, Li W, et al
    Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.
    Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30414.
    PubMed     Abstract available


  165. BERG S, Cole A, Trinh QD
    Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in P
    Eur Urol. 2019 Jun 4. pii: S0302-2838(19)30447.
    PubMed    


  166. WYATT AW, Chi KN, Gleave ME
    Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and P
    Eur Urol. 2019 Jun 2. pii: S0302-2838(19)30443.
    PubMed    


  167. VAN DER LEEST M, Israel B, Cornel EB, Zamecnik P, et al
    High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naive Men: The Next Step in Magnetic Resonance Imaging Accessibility.
    Eur Urol. 2019 Jun 2. pii: S0302-2838(19)30436.
    PubMed     Abstract available


  168. GUL ZG, Martini A, Olsson CA
    Re: Jacob A. Burns, Adam B. Weiner, William J. Catalone, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846-52.
    Eur Urol. 2019 Jun 1. pii: S0302-2838(19)30433.
    PubMed    


    May 2019
  169. SHAH TT, Peters M, Arya M, Ahmed HU, et al
    Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre
    Eur Urol. 2019 May 29. pii: S0302-2838(19)30427.
    PubMed    


  170. MAI Z
    Re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol. In press. https://doi.o
    Eur Urol. 2019 May 29. pii: S0302-2838(19)30428.
    PubMed    


  171. ROCCO B, Sighinolfi MC
    Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:285-93.
    Eur Urol. 2019 May 29. pii: S0302-2838(19)30437.
    PubMed    


  172. BURNS JA, Weiner AB, Kundu S
    Reply to Zeynep G. Gul, Alberto Martini, and Carl A. Olsson's Letter to the Editor re: Jacob A. Burns, Adam B. Weiner, William J. Catalona, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846-52.
    Eur Urol. 2019 May 28. pii: S0302-2838(19)30434.
    PubMed    


  173. AHMADZADEHFAR H, Essler M
    Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi
    Eur Urol. 2019 May 28. pii: S0302-2838(19)30435.
    PubMed    


  174. KOSCHEL SG, Wong LM, Heinze S, Zargar H, et al
    Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    Eur Urol. 2019 May 27. pii: S0302-2838(19)30424.
    PubMed    


  175. KASIVISVANATHAN V, Stabile A, Neves JB, Giganti F, et al
    Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30360.
    PubMed     Abstract available


  176. HADASCHIK B, Ost P
    Re: Assessment of (68)Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30420.
    PubMed    


  177. FROEHNER M, Thomas C
    Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30419.
    PubMed    


  178. COOPERBERG MR, Carroll PR, Dall'Era MA, Davies BJ, et al
    The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30417.
    PubMed     Abstract available


  179. WANG B, Deng H, Cao L
    Re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028.
    Eur Urol. 2019 May 17. pii: S0302-2838(19)30377.
    PubMed    


  180. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Usi
    Eur Urol. 2019 May 17. pii: S0302-2838(19)30379.
    PubMed    


  181. INARRITU JM, Castellani D, Teoh JYC
    Re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol. In press. https://doi.org/10.1016/j.eururo.
    Eur Urol. 2019 May 15. pii: S0302-2838(19)30378.
    PubMed    


  182. ALGHAZO O, Thangasamy I, Sathianathen N, Murphy DG, et al
    Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2019 May 14. pii: S0302-2838(19)30342.
    PubMed    


  183. GANDAGLIA G, Albers P, Abrahamsson PA, Briganti A, et al
    Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Eur Urol. 2019 May 12. pii: S0302-2838(19)30347.
    PubMed     Abstract available


  184. LIANG J, Beckta JM, Bindra RS
    Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. In press. h
    Eur Urol. 2019 May 9. pii: S0302-2838(19)30358.
    PubMed    


  185. SIERRA PS
    Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.048: Useful Prognostic Info
    Eur Urol. 2019 May 4. pii: S0302-2838(19)30355.
    PubMed    


  186. LOEB S
    Overactive Surveillance: Is "Conservative" Management for Low-risk Prostate Cancer Too Aggressive?
    Eur Urol. 2019 May 3. pii: S0302-2838(19)30282.
    PubMed    


  187. DONNELLY DW, Gavin A, Downing A, Hounsome L, et al
    Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom.
    Eur Urol. 2019 May 3. pii: S0302-2838(19)30329.
    PubMed     Abstract available


  188. MARGEL D, Ber Y, Baniel J
    Re: Optimizing Patient's Selection for Prostate Biopsy: A Single Institution Experience with Multi-parametric MRI and the 4Kscore Test for the Detection of Aggressive Prostate Cancer.
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30338.
    PubMed    


  189. SUARDI N
    Re: Active Surveillance of Prostate Cancer is a Viable Option in Men Younger than 60 Years.
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30341.
    PubMed    


  190. GNANAPRAGASAM VJ, Barrett T
    The Quest for the Optimal Prostate Biopsy Regime for the 21st Century.
    Eur Urol. 2019;75:741-742.
    PubMed    


  191. SINGH K, Tin AL, Dunn RL, Kim T, et al
    Development and Validation of Crosswalks for Patient-reported Sexual and Urinary Outcomes Between Commonly Used Instruments.
    Eur Urol. 2019;75:723-730.
    PubMed     Abstract available


    April 2019
  192. FLETCHER CE
    The Role of Splicing Regulators in the Emergence of Treatment-induced Neuroendocrine Prostate Cancer: The Next Generation of Drug Targets?
    Eur Urol. 2019 Apr 29. pii: S0302-2838(19)30328.
    PubMed    


  193. SHARP A, Welti JC, Lambros MBK, Dolling D, et al
    Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Apr 27. pii: S0302-2838(19)30285.
    PubMed     Abstract available


  194. DEVOS G, De Meerleer G, Joniau S
    Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?
    Eur Urol. 2019 Apr 25. pii: S0302-2838(19)30327.
    PubMed     Abstract available


  195. FRASER M
    Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Apr 19. pii: S0302-2838(19)30284.
    PubMed    


  196. SANDLER KA, Cook RR, Ciezki JP, Ross AE, et al
    Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
    Eur Urol. 2019 Apr 13. pii: S0302-2838(19)30208.
    PubMed     Abstract available


  197. MINERVINI A, Mari A, Campi R, Carini M, et al
    Re: Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial.
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30271.
    PubMed    


  198. KRETSCHMER A, Tilki D
    Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial.
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30260.
    PubMed    


  199. HORN T, Kronke M, Rauscher I, Haller B, et al
    Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30278.
    PubMed     Abstract available


  200. YAXLEY JW
    Will Favourable Functional Results with Salvage Robot-assisted Laparoscopic Radical Prostatectomy Increase the Uptake of Primary Focal Therapy for Localised Prostate Cancer?
    Eur Urol. 2019 Apr 9. pii: S0302-2838(19)30264.
    PubMed    


  201. STEINECK G, Akre O, Bill-Axelson A
    Solid Science for the Upside but Lack of Solid Science for the Downside-Towards Cutting-edge Prostate-cancer Screening.
    Eur Urol. 2019 Apr 8. pii: S0302-2838(19)30276.
    PubMed    


  202. VAN DEN BROECK T, Mottet N, Lam T
    Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A System
    Eur Urol. 2019 Apr 6. pii: S0302-2838(19)30255.
    PubMed    


  203. WERNTZ RP, Eggener SE
    Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015.
    Eur Urol. 2019 Apr 5. pii: S0302-2838(19)30274.
    PubMed    


  204. CATHELINEAU X, Macek P, Sanchez-Salas R
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2019 Apr 4. pii: S0302-2838(19)30262.
    PubMed    


  205. FRYDENBERG M
    Re: (68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2019 Apr 4. pii: S0302-2838(19)30272.
    PubMed    


  206. MATEO J, Carreira S, de Bono JS
    PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers.
    Eur Urol. 2019 Apr 3. pii: S0302-2838(19)30257.
    PubMed    


  207. STOCKLE M
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2019 Apr 1. pii: S0302-2838(19)30263.
    PubMed    


  208. ZHOU X, Han X
    Re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. In press. https://doi.org/10.1016/j.eu
    Eur Urol. 2019 Apr 1. pii: S0302-2838(19)30256.
    PubMed    


  209. SADUN TY, Reiter RE
    Adjusting Our Approach to Multiparametric Magnetic Resonance Imaging-based Targeted Prostate Biopsies: Considerations After the FUTURE Trial.
    Eur Urol. 2019;75:591-592.
    PubMed    


  210. MARKOWSKI MC, Boorjian SA, Burton JP, Hahn NM, et al
    The Microbiome and Genitourinary Cancer: A Collaborative Review.
    Eur Urol. 2019;75:637-646.
    PubMed     Abstract available


  211. VAN DER LEEST M, Cornel E, Israel B, Hendriks R, et al
    Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naive Men with Elevated Prostate-specific Antigen: A Large Prospectiv
    Eur Urol. 2019;75:570-578.
    PubMed     Abstract available


    March 2019
  212. CARLSSON SV, Mansson M, Moss S, Kwiatkowski M, et al
    Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30196.
    PubMed     Abstract available


  213. LEIBOWITZ-AMIT R
    Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur
    Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30199.
    PubMed    


  214. CHEN WS, Aggarwal R, Zhang L, Zhao SG, et al
    Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30206.
    PubMed     Abstract available


  215. LI Y, Xie N, Chen R, Lee AR, et al
    RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Eur Urol. 2019 Mar 22. pii: S0302-2838(19)30197.
    PubMed     Abstract available


  216. URABE F, Ochiya T, Egawa S
    Re: A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    Eur Urol. 2019 Mar 21. pii: S0302-2838(19)30183.
    PubMed    


  217. KNUDSEN KE, Feng FY
    Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset.
    Eur Urol. 2019 Mar 15. pii: S0302-2838(19)30191.
    PubMed    


  218. NAM RK
    Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years.
    Eur Urol. 2019 Mar 14. pii: S0302-2838(19)30189.
    PubMed    


  219. BRATT O, Holmberg E, Andren O, Carlsson S, et al
    The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).
    Eur Urol. 2019 Mar 13. pii: S0302-2838(19)30182.
    PubMed     Abstract available


  220. MOON DH, Basak RS, Usinger DS, Dickerson GA, et al
    Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
    Eur Urol. 2019 Mar 8. pii: S0302-2838(19)30169.
    PubMed     Abstract available


  221. NABID A, Souhami L
    Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, Andre-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31
    Eur Urol. 2019;75:e63.
    PubMed    


  222. CONTEDUCA V, Jayaram A, Romero-Laorden N, Wetterskog D, et al
    Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019;75:368-373.
    PubMed     Abstract available


  223. AHMADZADEHFAR H, Essler M
    Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30175.
    PubMed    


  224. WALZ J
    What Needs To Be Done Before Prostate Magnetic Resonance Imaging Can Safely Be Applied in the General Population.
    Eur Urol. 2019;75:397-398.
    PubMed    


  225. VAN HEMELRIJCK M, Ji X, Helleman J, Roobol MJ, et al
    Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
    Eur Urol. 2019;75:523-531.
    PubMed     Abstract available


  226. PADHANI AR, Weinreb J, Rosenkrantz AB, Villeirs G, et al
    Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.
    Eur Urol. 2019;75:385-396.
    PubMed     Abstract available


    February 2019
  227. KARNES RJ, Motterle G
    Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years.
    Eur Urol. 2019 Feb 28. pii: S0302-2838(19)30168.
    PubMed    


  228. HOFER L, Hohenfellner M
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2019 Feb 27. pii: S0302-2838(19)30164.
    PubMed    


  229. DARCEY E, Pereira G, Salter A, Fritschi L, et al
    The Impact of Lifestyle-related Factors on Survival After a Prostate Cancer Diagnosis.
    Eur Urol. 2019 Feb 27. pii: S0302-2838(19)30151.
    PubMed    


  230. BURDETT S, Boeve LM, Ingleby FC, Fisher DJ, et al
    Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.
    Eur Urol. 2019 Feb 27. pii: S0302-2838(19)30111.
    PubMed     Abstract available


  231. HUGOSSON J, Roobol MJ, Mansson M, Tammela TLJ, et al
    A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
    Eur Urol. 2019 Feb 26. pii: S0302-2838(19)30150.
    PubMed     Abstract available


  232. WALLIS CJD, Klotz L, Klaassen Z
    Re: Prostate Cancer-specific Mortality Across Gleason Scores in Black vs Nonblack Men.
    Eur Urol. 2019 Feb 25. pii: S0302-2838(19)30162.
    PubMed    


  233. PRENSNER JR, Feng FY
    "Lincing" the Y Chromosome to Prostate Cancer: TTTY15 Takes Center Stage.
    Eur Urol. 2019 Feb 21. pii: S0302-2838(19)30158.
    PubMed    


  234. WIRTH M, Fossati N, Albers P, Bangma C, et al
    The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting.
    Eur Urol. 2019 Feb 21. pii: S0302-2838(19)30077.
    PubMed     Abstract available


  235. MARSHALL CH, Sokolova AO, McNatty AL, Cheng HH, et al
    Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Eur Urol. 2019 Feb 20. pii: S0302-2838(19)30110.
    PubMed     Abstract available


  236. LEONGAMORNLERT DA, Saunders EJ, Wakerell S, Whitmore I, et al
    Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
    Eur Urol. 2019 Feb 15. pii: S0302-2838(19)30096.
    PubMed     Abstract available


  237. SHORT CE, Trinh L, James EL
    Effective Technology-based Behaviour Change Interventions in Prostate Cancer Supportive Care: Are We There Yet?
    Eur Urol. 2019 Feb 15. pii: S0302-2838(19)30109.
    PubMed    


  238. PERERA M, Papa N, Roberts M, Williams M, et al
    Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and M
    Eur Urol. 2019 Feb 14. pii: S0302-2838(19)30095.
    PubMed     Abstract available


  239. MURTOLA TJ, Syvala H, Riikonen J
    Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Cl
    Eur Urol. 2019 Feb 6. pii: S0302-2838(19)30090.
    PubMed    


  240. KIM JH, Chung BI
    Re: Timu J. Murtola, Hemo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701.
    Eur Urol. 2019 Feb 6. pii: S0302-2838(19)30088.
    PubMed    


  241. VALE S
    Re: Rano Matta, Christopher J.D. Wallis, Mitchell G. Goldenberg, et al. Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. Eur Urol 2019;75:3-7: Translati
    Eur Urol. 2019 Feb 4. pii: S0302-2838(19)30089.
    PubMed    


  242. BENOIST GE, van Oort IM, Burger DM, Koch BCP, et al
    The Combination of Enzalutamide and Opioids: A Painful Pitfall?
    Eur Urol. 2019;75:351-352.
    PubMed    


  243. CAPOGROSSO P, Vertosick EA, Benfante NE, Eastham JA, et al
    Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade.
    Eur Urol. 2019;75:221-228.
    PubMed     Abstract available


  244. KLOTZ L, Loblaw A, Sugar L, Moussa M, et al
    Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
    Eur Urol. 2019;75:300-309.
    PubMed     Abstract available


    January 2019
  245. SHOAG JE, Tosoian JJ, Salami SS, Barbieri CE, et al
    Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30070.
    PubMed    


  246. VOLTA AD, Formenti A, Berruti A
    Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
    Eur Urol. 2019 Jan 30. pii: S0302-2838(19)30069.
    PubMed     Abstract available


  247. LOEB S, Taylor J, Butaney M, Byrne NK, et al
    Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination.
    Eur Urol. 2019 Jan 30. pii: S0302-2838(19)30068.
    PubMed    


  248. HOULAHAN KE, Salmasi A, Sadun TY, Pooli A, et al
    Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.
    Eur Urol. 2019 Jan 24. pii: S0302-2838(18)31044.
    PubMed     Abstract available


  249. MAHAL BA, Alshalalfa M, Spratt DE, Davicioni E, et al
    Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores.
    Eur Urol. 2019 Jan 22. pii: S0302-2838(19)30011.
    PubMed    


  250. KISHAN AU, Hall WA, Spratt DE
    Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. In press.
    Eur Urol. 2019 Jan 19. pii: S0302-2838(19)30017.
    PubMed    


  251. COLE AP, Trinh QD
    Reply to Amar U. Kishan, William Hall, and Daniel Spratt's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachyth
    Eur Urol. 2019 Jan 19. pii: S0302-2838(19)30018.
    PubMed    


  252. SEMJONOW A, Hense HW, Schlossler K, Simbrich A, et al
    Development and Prospective Randomized Evaluation of a Decision Aid for Prostate-specific Antigen-based Early Detection of Prostate Cancer in Men Aged Between 55 and 69Yr: The PSAInForm Trial.
    Eur Urol. 2019 Jan 18. pii: S0302-2838(19)30009.
    PubMed     Abstract available


  253. CASTILLO-JIMENEZ DA, Garcia-Perdomo HA
    Re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press
    Eur Urol. 2019 Jan 18. pii: S0302-2838(19)30013.
    PubMed    


  254. SATHIANATHEN NJ, Konety BR
    Reply to Diana A. Castillo-Jimenez and Herney A. Garcia-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of A
    Eur Urol. 2019 Jan 18. pii: S0302-2838(19)30020.
    PubMed    


  255. ON BEHALF OF EMA
    Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.'s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eu
    Eur Urol. 2019 Jan 15. pii: S0302-2838(18)30957.
    PubMed    


  256. ZLOTTA AR, Kuk C
    Further Evidence of Differences in Prostate Cancer Biomarkers Between Caucasian and Asian Men.
    Eur Urol. 2019 Jan 11. pii: S0302-2838(18)31046.
    PubMed    


  257. CARNEIRO B, Dizon DS
    Prostate Cancer Social Media: In YouTube We Trust?
    Eur Urol. 2019 Jan 10. pii: S0302-2838(19)30005.
    PubMed    


  258. SOORIAKUMARAN P, Pavan N, Wiklund PN, Roach M 3rd, et al
    Surgery Versus Radiation for High-risk Prostate Cancer: The Fight Continues. But Is It Time To Call a Draw and Reach Consensus?
    Eur Urol. 2019 Jan 10. pii: S0302-2838(18)31040.
    PubMed    


  259. KENFIELD SA, Van Blarigan EL, Ameli N, Lavaki E, et al
    Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer.
    Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31048.
    PubMed     Abstract available


  260. VANDEKERKHOVE G, Struss WJ, Annala M, Kallio HML, et al
    Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31050.
    PubMed     Abstract available


  261. SHAH TT, Peters M, Eldred-Evans D, Miah S, et al
    Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.
    Eur Urol. 2019 Jan 8. pii: S0302-2838(18)31036.
    PubMed     Abstract available


  262. MURPHY DG, Azad AA, Sandhu S, Violet J, et al
    Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31047.
    PubMed    


  263. CIRIACO P, Briganti A, Bernabei A, Gandaglia G, et al
    Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience.
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31035.
    PubMed     Abstract available


  264. VIS AN, Boeve LMS
    Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31029.
    PubMed    


  265. KRETSCHMER A, Gleave ME
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE).
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31043.
    PubMed    


  266. HEIDEGGER I, Pichler R
    Re: Peter K.-F. Chiu, Chi-Fai Ng, Axel Semjonow, et al. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asia
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31049.
    PubMed    


  267. YANG DD, Mahal BA, Muralidhar V, Martin NE, et al
    Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Eur Urol. 2019;75:35-41.
    PubMed     Abstract available


  268. MORGANS AK
    An Imprecise Path to Precision Medicine.
    Eur Urol. 2019;75:193-194.
    PubMed    


  269. ZHOU AG, Salles DC, Samarska IV, Epstein JI, et al
    How Are Gleason Scores Categorized in the Current Literature: An Analysis and Comparison of Articles Published in 2016-2017.
    Eur Urol. 2019;75:25-31.
    PubMed     Abstract available


    December 2018
  270. KHALAF DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, et al
    Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)31020.
    PubMed     Abstract available


  271. DI LORENZO G, Buonerba C
    Oligometastatic Prostate Cancer: Is it Only a Matter of Perspective?
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)30998.
    PubMed     Abstract available


  272. GREGUCCI F, Fiorentino A
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)31030.
    PubMed    


  273. DENTON BT, Hawley ST, Morgan TM
    Optimizing Prostate Cancer Surveillance: Using Data-driven Models for Informed Decision-making.
    Eur Urol. 2018 Dec 18. pii: S0302-2838(18)30965.
    PubMed    


  274. LOHAUS F, Zophel K, Lock S, Wirth M, et al
    Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
    Eur Urol. 2018 Dec 18. pii: S0302-2838(18)30954.
    PubMed     Abstract available


  275. MATTA R, Chapple CR, Fisch M, Heidenreich A, et al
    Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
    Eur Urol. 2018 Dec 17. pii: S0302-2838(18)30962.
    PubMed     Abstract available


  276. OSTERGREN PB, Murtola TJ, Fode M
    Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2.
    Eur Urol. 2018 Dec 17. pii: S0302-2838(18)31021.
    PubMed    


  277. PADHANI AR, Haider MA, Villers A, Barentsz JO, et al
    Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss.
    Eur Urol. 2018 Dec 15. pii: S0302-2838(18)30963.
    PubMed    


  278. WEI Y, Li T, Liu L
    Re: Alberto Briganti, Nicola Fossati, James W.F. Catto, et al. Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:357-68.
    Eur Urol. 2018 Dec 15. pii: S0302-2838(18)31001.
    PubMed    


  279. GOKCE A, Gul D
    Re: Mark Douglas Tyson II, Tatsuki Koyama, Dan Lee, et al. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. Eur Urol 2018;74:26-33.
    Eur Urol. 2018 Dec 14. pii: S0302-2838(18)31000.
    PubMed    


  280. DAL PRA A, Abramowitz M, Pollack A
    Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and Selection.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30958.
    PubMed    


  281. HAMID AA, Gray KP, Shaw G, MacConaill LE, et al
    Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30949.
    PubMed     Abstract available


  282. NYBERG T, Govindasami K, Leslie G, Dadaev T, et al
    Homeobox B13 G84E Mutation and Prostate Cancer Risk.
    Eur Urol. 2018 Dec 7. pii: S0302-2838(18)30872.
    PubMed     Abstract available


  283. XIAO G, Yao J, Kong D, Ye C, et al
    The Long Noncoding RNA TTTY15, Which Is Located on the Y Chromosome, Promotes Prostate Cancer Progression by Sponging let-7.
    Eur Urol. 2018 Dec 7. pii: S0302-2838(18)30869.
    PubMed     Abstract available


  284. RUD E, Lauritzen P, Baco E
    Re: Henrik Gronberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.06.022.
    Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30951.
    PubMed    


  285. BASCH EM, Scholz M, de Bono JS, Vogelzang N, et al
    Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
    Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30932.
    PubMed     Abstract available


  286. BURNS JA, Weiner AB, Catalona WJ, Li EV, et al
    Inflammatory Bowel Disease and the Risk of Prostate Cancer.
    Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30938.
    PubMed     Abstract available


  287. WEGELIN O, Exterkate L, van der Leest M, Kummer JA, et al
    The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
    Eur Urol. 2018 Dec 3. pii: S0302-2838(18)30939.
    PubMed     Abstract available


  288. EKLUND M, Strom P, Gronberg H, Nordstrom T, et al
    Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Gronberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance
    Eur Urol. 2018 Dec 1. pii: S0302-2838(18)30950.
    PubMed    


  289. SARTOR O
    Synergistic Interactions: Targeted Radiopharmaceuticals and Homologous Recombination Repair Alterations in Prostate Cancer.
    Eur Urol. 2018 Dec 1. pii: S0302-2838(18)30940.
    PubMed    


  290. KEARNS JT, Newcomb LF, Lin DW
    Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Stud
    Eur Urol. 2018;74:e151.
    PubMed    


  291. YUAN R
    Re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12.
    Eur Urol. 2018;74:e149-e150.
    PubMed    


    November 2018
  292. JOHNSON DC, Raman SS, Mirak SA, Kwan L, et al
    Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    Eur Urol. 2018 Nov 30. pii: S0302-2838(18)30930.
    PubMed     Abstract available


  293. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostat
    Eur Urol. 2018 Nov 30. pii: S0302-2838(18)30942.
    PubMed    


  294. BOEVE LMS, Vis AN
    Reply to Herney Andres Garcia-Perdomo's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurr
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30933.
    PubMed    


  295. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30941.
    PubMed    


  296. HAMID S, Donaldson IA, Hu Y, Rodell R, et al
    The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification.
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30592.
    PubMed     Abstract available


  297. DE BRUYCKER A, De Bleser E, Decaestecker K, Fonteyne V, et al
    Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.
    Eur Urol. 2018 Nov 28. pii: S0302-2838(18)30839.
    PubMed     Abstract available


  298. FIORENTINO A, Errico A, Scarcia M
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30881.
    PubMed    


  299. LOEB S, Sengupta S, Butaney M, Macaluso JN Jr, et al
    Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30854.
    PubMed     Abstract available


  300. ZHOU Z, Zhou Y, Yan W
    Re: Stephanie Guillaumier, Max Peters, Manit Arya, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol 2018;74:422-9.
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30935.
    PubMed    


  301. BECKMANN K, Garmo H, Adolfsson J, Bosco C, et al
    Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Eur Urol. 2018 Nov 26. pii: S0302-2838(18)30879.
    PubMed     Abstract available


  302. GARCIA-PERDOMO HA
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Nov 23. pii: S0302-2838(18)30929.
    PubMed    


  303. ZAORSKY NG, Spratt DE, Blanchard P
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30882.
    PubMed    


  304. LAM TBL, MacLennan S, Plass K, Willemse PM, et al
    Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer.
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30866.
    PubMed    


  305. HECK MM, Tauber R, Schwaiger S, Retz M, et al
    Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30873.
    PubMed     Abstract available


  306. CIMADAMORE A, Scarpelli M, Santoni M, Cheng L, et al
    Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vas
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30895.
    PubMed    


  307. BOEVE LMS, Verhagen PCMS, Vis AN
    Reply to Ashwin Shinde, Richard Li, Arya Amini, and Scott Glaser's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Th
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30864.
    PubMed    


  308. TILKI D, Evans CP
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial.
    Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30868.
    PubMed    


  309. MAHON KL, Qu W, Lin HM, Spielman C, et al
    Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
    Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30855.
    PubMed     Abstract available


  310. MATEO J, Carles J
    Towards a New Classification for Metastatic Prostate Cancer.
    Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30862.
    PubMed    


  311. SHINDE A, Li R, Amini A, Glaser S, et al
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Nov 18. pii: S0302-2838(18)30865.
    PubMed    


  312. O'SULLIVAN JM, Heinrich D, James ND, Nilsson S, et al
    The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Nov 16. pii: S0302-2838(18)30857.
    PubMed    


  313. DE MAN K, Ost P
    Re: [(177)Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study.
    Eur Urol. 2018 Nov 14. pii: S0302-2838(18)30859.
    PubMed    


  314. SATHIANATHEN NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, et al
    Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Eur Urol. 2018 Nov 10. pii: S0302-2838(18)30853.
    PubMed     Abstract available


  315. BERG S, Cole AP, Krimphove MJ, Nabi J, et al
    Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer.
    Eur Urol. 2018 Nov 9. pii: S0302-2838(18)30820.
    PubMed     Abstract available


  316. OSSES DF, Remmers S, Schroder FH, van der Kwast T, et al
    Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
    Eur Urol. 2018 Nov 9. pii: S0302-2838(18)30851.
    PubMed     Abstract available


  317. GANDAGLIA G, Soligo M, Battaglia A, Muilwijk T, et al
    Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
    Eur Urol. 2018 Nov 5. pii: S0302-2838(18)30837.
    PubMed     Abstract available


  318. CHIU PK, Ng CF, Semjonow A, Zhu Y, et al
    A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.
    Eur Urol. 2018 Nov 2. pii: S0302-2838(18)30842.
    PubMed     Abstract available


    October 2018
  319. CANTER DJ, Reid J, Latsis M, Variano M, et al
    Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30816.
    PubMed     Abstract available


  320. PLOUSSARD G, Gandaglia G, Borgmann H, de Visschere P, et al
    Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30836.
    PubMed     Abstract available


  321. BRATT O, Lamb AD
    Genetic Reasons to Walk the Extra Mile to Prevent Prostate Cancer.
    Eur Urol. 2018 Oct 29. pii: S0302-2838(18)30807.
    PubMed    


  322. GHADJAR P, Wiegel T
    Re: Abdenour Nabid, Nathalie Carrier, Andre-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.
    Eur Urol. 2018 Oct 26. pii: S0302-2838(18)30818.
    PubMed    


  323. ROOBOL MJ
    Active Surveillance for Low-risk Prostate Cancer: Will it Become Obsolete?
    Eur Urol. 2018 Oct 25. pii: S0302-2838(18)30809.
    PubMed    


  324. GANDAGLIA G, Ploussard G, Valerio M, Mattei A, et al
    A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.
    Eur Urol. 2018 Oct 17. pii: S0302-2838(18)30753.
    PubMed     Abstract available


  325. VAN DEN BROECK T, van den Bergh RCN, Arfi N, Gross T, et al
    Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
    Eur Urol. 2018 Oct 17. pii: S0302-2838(18)30752.
    PubMed     Abstract available


  326. ZAFEIRIOU Z, Bianchini D, Chandler R, Rescigno P, et al
    Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
    Eur Urol. 2018 Oct 16. pii: S0302-2838(18)30738.
    PubMed     Abstract available


  327. ANTONARAKIS ES, Shaukat F, Isaacsson Velho P, Kaur H, et al
    Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30750.
    PubMed     Abstract available


  328. KASIVISVANATHAN V, Ambrosi A, Giganti F, Chau E, et al
    A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI.
    Eur Urol. 2018 Oct 13. pii: S0302-2838(18)30721.
    PubMed    


  329. VICKERS AJ, Lilja H, Assel M
    Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-u
    Eur Urol. 2018 Oct 13. pii: S0302-2838(18)30743.
    PubMed    


  330. PENNEY KL, Loda M, Stampfer MJ
    Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
    Eur Urol. 2018 Oct 12. pii: S0302-2838(18)30744.
    PubMed    


  331. AUFFENBERG GB, Ghani KR, Ramani S, Usoro E, et al
    askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men.
    Eur Urol. 2018 Oct 11. pii: S0302-2838(18)30740.
    PubMed     Abstract available


  332. CARTER HB, Helfand B, Mamawala M, Wu Y, et al
    Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Oct 8. pii: S0302-2838(18)30684.
    PubMed     Abstract available


  333. PERNAR CH, Ebot EM, Pettersson A, Graff RE, et al
    A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
    Eur Urol. 2018 Oct 6. pii: S0302-2838(18)30730.
    PubMed     Abstract available


  334. FOSSATI N, Suardi N, Gandaglia G, Bravi CA, et al
    Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
    Eur Urol. 2018 Oct 6. pii: S0302-2838(18)30659.
    PubMed     Abstract available


  335. MOSCHINI M, Zaffuto E, Karakiewicz PI, Andrea DD, et al
    External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30722.
    PubMed     Abstract available


  336. ISAACSSON VELHO P, Qazi F, Hassan S, Carducci MA, et al
    Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30729.
    PubMed     Abstract available


  337. CULIG Z
    Identification of Potential Novel Candidates for Understanding Racial Differences in Prostate Cancer.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30726.
    PubMed    


  338. SIVA S, Bressel M, Murphy DG, Shaw M, et al
    Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
    Eur Urol. 2018;74:455-462.
    PubMed     Abstract available


  339. TOSCO L, Briganti A, D'amico AV, Eastham J, et al
    Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.
    Eur Urol. 2018 Oct 1. pii: S0302-2838(18)30549.
    PubMed     Abstract available


  340. OST P
    It Ain't Over Till the Fat Lady Sings: The POPSTAR Trial.
    Eur Urol. 2018;74:463-464.
    PubMed    


  341. GORIN MA, Walsh PC
    Magnetic Resonance Imaging Prior to First Prostate Biopsy-Are we there yet?
    Eur Urol. 2018;74:409-410.
    PubMed    


    September 2018
  342. NORDSTROM T, Lindberg J, Eklund M
    Towards Next-generation Urine-based Prostate Cancer Risk Stratification.
    Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30709.
    PubMed    


  343. OISHI M, Gill IS, Ashrafi AN, Lin-Brande M, et al
    Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
    Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30654.
    PubMed     Abstract available


  344. GRAFF RE, Kachuri L, Witte JS
    Personalized Prostate Cancer Screening Based on a Single Midlife Prostate-specific Antigen Measurement.
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30681.
    PubMed    


  345. DEEK MP, Phillips RM, Haffner M, Tran PT, et al
    Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30715.
    PubMed    


  346. BOEVE LMS, Hulshof MCCM, Vis AN, Zwinderman AH, et al
    Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical
    Eur Urol. 2018 Sep 25. pii: S0302-2838(18)30658.
    PubMed     Abstract available


  347. SHINDE A, Li R, Glaser S, Amini A, et al
    Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging?
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30667.
    PubMed     Abstract available


  348. TONON L, Fromont G, Boyault S, Thomas E, et al
    Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.
    Eur Urol. 2018 Sep 20. pii: S0302-2838(18)30618.
    PubMed     Abstract available


  349. MATTA R, Wallis CJD, Goldenberg MG, Hird AE, et al
    Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study.
    Eur Urol. 2018 Sep 18. pii: S0302-2838(18)30630.
    PubMed     Abstract available


  350. PRESTON MA, Gerke T, Carlsson SV, Signorello L, et al
    Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30627.
    PubMed     Abstract available


  351. VAN DER POEL HG, van den Bergh RCN, Briers E, Cornford P, et al
    Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Posi
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30645.
    PubMed    


  352. MCKIERNAN J, Donovan MJ, Margolis E, Partin A, et al
    A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30604.
    PubMed     Abstract available


  353. WEINER AB, Schaeffer EM, Eggener SE
    "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Sep 14. pii: S0302-2838(18)30643.
    PubMed    


  354. VALERIO M, Emberton M, Ahmed HU
    Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
    Eur Urol. 2018 Sep 14. pii: S0302-2838(18)30646.
    PubMed    


  355. WALLIS CJD, Krakowsky Y, Finelli A
    Low Testosterone and Prostate Cancer: Is the Protection Real?
    Eur Urol. 2018 Sep 5. pii: S0302-2838(18)30616.
    PubMed    


  356. LOVF M, Zhao S, Axcrona U, Johannessen B, et al
    Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
    Eur Urol. 2018 Sep 1. pii: S0302-2838(18)30594.
    PubMed     Abstract available


  357. KENDALL MC
    Re: Karl H. Pang, Ruth Groves, Suresh Venugopal, Aidan P. Noon, James W.F. Catto. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol 2018;73:363-71.
    Eur Urol. 2018;74:e65.
    PubMed    


  358. PANG KH, Groves R, Catto JWF
    Reply to Mark C. Kendall's Letter to the Editor re: Karl H. Pang, Ruth Groves, Suresh Venugopal, Aidan P. Noon, James W.F. Catto. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol 2018;73:363-71.
    Eur Urol. 2018;74:e66.
    PubMed    


    August 2018
  359. ALLOTT EH, Freeman MR, Freedland SJ
    Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30597.
    PubMed    


  360. DALL'ERA MA, De Vere White RW
    New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose?
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30599.
    PubMed    


  361. GINSBURG KB, Auffenberg GB, Qi J, Powell IJ, et al
    Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30595.
    PubMed     Abstract available


  362. MASON M
    Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30563.
    PubMed    


  363. FONTEYNE V, Ost P
    Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than Answers.
    Eur Urol. 2018 Aug 30. pii: S0302-2838(18)30598.
    PubMed    


  364. REIS LO
    Metastasis-free Survival-Progress or Lowering the Bar on Nonmetastatic Prostate Cancer?
    Eur Urol. 2018 Aug 28. pii: S0302-2838(18)30603.
    PubMed    


  365. FORSMARK A, Gehrman J, Angenete E, Bjartell A, et al
    Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial.
    Eur Urol. 2018 Aug 21. pii: S0302-2838(18)30560.
    PubMed     Abstract available


  366. MATEO J, Fizazi K, Gillessen S, Heidenreich A, et al
    Managing Nonmetastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Aug 14. pii: S0302-2838(18)30557.
    PubMed     Abstract available


  367. CIMADAMORE A, Scarpelli M, Cheng L, Lopez-Beltran A, et al
    Re: Isabel Rauscher, Charlotte Duwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Rec
    Eur Urol. 2018 Aug 6. pii: S0302-2838(18)30556.
    PubMed    


  368. MONTIRONI R, Cheng L, Cimadamore A, Lopez-Beltran A, et al
    Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?
    Eur Urol. 2018 Aug 6. pii: S0302-2838(18)30555.
    PubMed    


  369. ALBERTS AR, Roobol MJ, Verbeek JFM, Schoots IG, et al
    Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Eur Urol. 2018 Aug 3. pii: S0302-2838(18)30553.
    PubMed     Abstract available


  370. WATTS EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, et al
    Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.
    Eur Urol. 2018 Aug 1. pii: S0302-2838(18)30546.
    PubMed     Abstract available


    July 2018
  371. BOUTROS PC
    The Promise and Perils of Sequencing Individual Prostate Cancer Nuclei.
    Eur Urol. 2018 Jul 31. pii: S0302-2838(18)30550.
    PubMed    


  372. D'ANDREA D, Shariat SF, Soria F
    Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
    Eur Urol. 2018 Jul 30. pii: S0302-2838(18)30544.
    PubMed    


  373. PREISSER F, Mazzone E, Nazzani S, Bandini M, et al
    Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer.
    Eur Urol. 2018 Jul 20. pii: S0302-2838(18)30484.
    PubMed     Abstract available


  374. CAVARRETTA I, Mancini N, Salonia A
    Analysis of the Enteric Microbiome: First Tentative Steps Towards a Comprehensive Work-up of Prostate Cancer?
    Eur Urol. 2018 Jul 20. pii: S0302-2838(18)30509.
    PubMed    


  375. MURTOLA TJ, Syvala H, Tolonen T, Helminen M, et al
    Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.
    Eur Urol. 2018 Jul 18. pii: S0302-2838(18)30465.
    PubMed     Abstract available


  376. MODI PK, Morgan TM
    Tradeoffs in Refining the Diagnosis of Prostate Cancer.
    Eur Urol. 2018 Jul 18. pii: S0302-2838(18)30486.
    PubMed    


  377. COONEY KA, Beebe-Dimmer JL
    Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes.
    Eur Urol. 2018 Jul 17. pii: S0302-2838(18)30479.
    PubMed    


  378. MAHAL BA, Yang DD, Nguyen PL
    Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. htt
    Eur Urol. 2018 Jul 17. pii: S0302-2838(18)30471.
    PubMed    


  379. LAWRENCE MG, Obinata D, Sandhu S, Selth LA, et al
    Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
    Eur Urol. 2018 Jul 13. pii: S0302-2838(18)30445.
    PubMed     Abstract available


  380. CRABB SJ
    Therapeutic Discovery for Castration Resistant Prostate Cancer: Patient-derived Xenograft Modelling Brings New Options to the Table.
    Eur Urol. 2018 Jul 12. pii: S0302-2838(18)30477.
    PubMed    


  381. LEPPERT JT, Brooks JD
    Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.01.043.
    Eur Urol. 2018 Jul 12. pii: S0302-2838(18)30472.
    PubMed    


  382. LISS MA, White JR, Goros M, Gelfond J, et al
    Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer.
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30461.
    PubMed     Abstract available


  383. MURPHY DG, Tilki D
    Getting the Balance Right-The Benefits and Uncertainties of Focal Therapy for Significant Prostate Cancer.
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30463.
    PubMed    


  384. SWEENEY CJ
    Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30464.
    PubMed    


  385. GRONBERG H, Eklund M, Picker W, Aly M, et al
    Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
    Eur Urol. 2018 Jul 9. pii: S0302-2838(18)30447.
    PubMed     Abstract available


  386. LI W, Middha M, Bicak M, Sjoberg DD, et al
    Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
    Eur Urol. 2018 Jul 7. pii: S0302-2838(18)30446.
    PubMed     Abstract available


  387. NABID A, Carrier N, Martin AG, Bahary JP, et al
    Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.
    Eur Urol. 2018 Jul 3. pii: S0302-2838(18)30443.
    PubMed     Abstract available


  388. XIE W, D'Amico AV
    Eighteen Months of Androgen Deprivation Therapy in Men with High-risk Prostate Cancer and the Risk of Death.
    Eur Urol. 2018 Jul 2. pii: S0302-2838(18)30451.
    PubMed    


  389. MOORE C
    Can Negative Prostate Magnetic Resonance Imaging Give Us the Reassurance We Need To Avoid Standard Biopsy? An Evidence-based Practical Approach.
    Eur Urol. 2018;74:55-56.
    PubMed    


  390. GANDAGLIA G, Bravi CA, Dell'Oglio P, Mazzone E, et al
    The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy.
    Eur Urol. 2018;74:4-7.
    PubMed     Abstract available


  391. OGAYA-PINIES G, Kadakia Y, Palayapalayam-Ganapathi H, Woodlief T, et al
    Use of Scaffolding Tissue Biografts To Bolster Vesicourethral Anastomosis During Salvage Robot-assisted Prostatectomy Reduces Leak Rates and Catheter Times.
    Eur Urol. 2018;74:92-98.
    PubMed     Abstract available


    June 2018
  392. GUILLAUMIER S, Peters M, Arya M, Afzal N, et al
    A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
    Eur Urol. 2018 Jun 27. pii: S0302-2838(18)30431.
    PubMed     Abstract available


  393. SU F, Zhang W, Zhang D, Zhang Y, et al
    Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
    Eur Urol. 2018 Jun 22. pii: S0302-2838(18)30430.
    PubMed     Abstract available


  394. BRIGANTI A, Fossati N, Catto JWF, Cornford P, et al
    Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Jun 21. pii: S0302-2838(18)30433.
    PubMed     Abstract available


  395. HAIDL F, Pfister D, Heidenreich A
    Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients.
    Eur Urol. 2018 Jun 15. pii: S0302-2838(18)30419.
    PubMed    


  396. WILCZAK W, Wittmer C, Clauditz T, Minner S, et al
    Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.
    Eur Urol. 2018 Jun 13. pii: S0302-2838(18)30423.
    PubMed     Abstract available


  397. SPRATT DE, Schaeffer EM
    Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk.
    Eur Urol. 2018 Jun 12. pii: S0302-2838(18)30426.
    PubMed    


  398. AMINSHARIFI A, Polascik TJ
    Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer.
    Eur Urol. 2018 Jun 8. pii: S0302-2838(18)30420.
    PubMed    


  399. NAIR R, Porpiglia F, Zargar H
    Re: MRI-targeted or Standard Biopsy for Prostate-cancer Diagnosis.
    Eur Urol. 2018 Jun 6. pii: S0302-2838(18)30418.
    PubMed    


  400. MEHRA N, Dolling D, de Bono J
    Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant P
    Eur Urol. 2018 Jun 1. pii: S0302-2838(18)30364.
    PubMed    


  401. BHINDI B, Karnes RJ
    Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Jun 1. pii: S0302-2838(18)30370.
    PubMed    


  402. MONTIRONI R, Cheng L, Lopez-Beltran A, Scarpelli M, et al
    Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy.
    Eur Urol. 2018;73:978-980.
    PubMed    


  403. LOMBARDO R, Bosch JLHR, Burkhard FC, Tubaro A, et al
    Re: A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control After Robotic Assisted Radical Prostatectomy.
    Eur Urol. 2018;73:980-981.
    PubMed    


  404. SPAHN M, Fehr JL
    Multiparametric Magnetic Resonance Imaging for Prostate-specific Antigen Recurrence After Radical Prostatectomy: Are We Leaving the "One Treatment Fits All Approach" and Moving Towards Personalized Imaging-guided Treatment?
    Eur Urol. 2018;73:888-889.
    PubMed    


  405. EGGENER S
    Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment.
    Eur Urol. 2018;73:897-898.
    PubMed    


  406. KASS-ILIYYA A, Jovic G, Murphy C, Fisher C, et al
    Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
    Eur Urol. 2018;73:968-976.
    PubMed     Abstract available


  407. SHARMA V, Nehra A, Colicchia M, Westerman ME, et al
    Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
    Eur Urol. 2018;73:879-887.
    PubMed     Abstract available


    May 2018
  408. COOPERBERG MR, Erho N, Chan JM, Feng FY, et al
    The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.
    Eur Urol. 2018 May 28. pii: S0302-2838(18)30362.
    PubMed     Abstract available


  409. CONTEDUCA V, Gurioli G, De Giorgi U
    Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press.
    Eur Urol. 2018 May 23. pii: S0302-2838(18)30363.
    PubMed    


  410. LUGHEZZANI G, Buffi NM, Lazzeri M
    Diagnostic Pathway of Patients with a Clinical Suspicion of Prostate Cancer: Does One Size Fit All?
    Eur Urol. 2018 May 23. pii: S0302-2838(18)30361.
    PubMed    


  411. DONOVAN JL, Hamdy FC
    Time for a "Radical" Change to Active Surveillance for Prostate Cancer?
    Eur Urol. 2018 May 17. pii: S0302-2838(18)30357.
    PubMed    


  412. VICKERS A, Nordstrom T, Assel M, Lilja H, et al
    Re: Tobias Nordstrom, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Gronberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139-46.
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30333.
    PubMed    


  413. GONG J, Omlin A, Pal SK, Hsu J, et al
    Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer.
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30330.
    PubMed    


  414. KNIPPER S, Graefen M
    Palliative Radical Prostatectomy in Men with Metastatic Castration-resistant Prostate Cancer: Only When Your Back Is Against the Wall!
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30334.
    PubMed    


  415. CAMPODONICO F, Ennas M, Introini C
    Re: Ettore Di Trapani, Alessandro Nini, Irene Locatelli, et al. Development of the First Model of Radical Prostatectomy in the Mouse: A Feasibility Study. Eur Urol 2018;73:482-4.
    Eur Urol. 2018;73:e133.
    PubMed    


  416. AVULOVA S, Smith JA Jr
    Is Comparison of Robotic to Open Radical Prostatectomy Still Relevant?
    Eur Urol. 2018;73:672-673.
    PubMed    


  417. CHIN JL
    Re: Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.
    Eur Urol. 2018;73:808.
    PubMed    


  418. MONTIRONI R, Cheng L, Scarpelli M, Lopez-Beltran A, et al
    From Gleason Grading System and High-grade Tertiary Patterns to Grade Groups and Integrated Quantitative Gleason Score.
    Eur Urol. 2018;73:684-686.
    PubMed    


  419. KEARNS JT, Faino AV, Newcomb LF, Brooks JD, et al
    Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
    Eur Urol. 2018;73:706-712.
    PubMed     Abstract available


  420. THOMPSON JE, Egger S, Bohm M, Siriwardana AR, et al
    Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases.
    Eur Urol. 2018;73:664-671.
    PubMed     Abstract available


  421. SAUTER G, Clauditz T, Steurer S, Wittmer C, et al
    Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.
    Eur Urol. 2018;73:674-683.
    PubMed     Abstract available


    April 2018
  422. SANCHEZ-SALAS R, de la Rosette J, Polascik TJ, Carneiro A, et al
    Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients.
    Eur Urol. 2018 Apr 30. pii: S0302-2838(18)30320.
    PubMed     Abstract available


  423. ABDOLLAH F, Dalela D, Sood A, Keeley J, et al
    Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection.
    Eur Urol. 2018 Apr 29. pii: S0302-2838(18)30318.
    PubMed     Abstract available


  424. HEINRICH D, Russnes KM, Oldenburg J
    Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Eur Urol. 2018 Apr 21. pii: S0302-2838(18)30277.
    PubMed    


  425. TOUIJER K
    Reply to Pim J. van Leeuwen and Henk G. van der Poel's Letter to the Editor re: Karim A. Touijer, Robert J. Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative An
    Eur Urol. 2018 Apr 21. pii: S0302-2838(18)30259.
    PubMed    


  426. WALZ J
    Re: Surveillance or Metastasis-directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
    Eur Urol. 2018 Apr 18. pii: S0302-2838(18)30255.
    PubMed    


  427. HAN S, Woo S, Kim YJ, Suh CH, et al
    Impact of (68)Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2018 Apr 17. pii: S0302-2838(18)30248.
    PubMed     Abstract available


  428. NUHN P, De Bono JS, Fizazi K, Freedland SJ, et al
    Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Eur Urol. 2018 Apr 16. pii: S0302-2838(18)30246.
    PubMed     Abstract available


  429. VAN LEEUWEN PJ, van der Poel HG
    Re: Karim A. Touijer, Robert Jeffery Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol. In p
    Eur Urol. 2018 Apr 13. pii: S0302-2838(18)30258.
    PubMed    


  430. VAN STAM MA, van der Poel H
    The New Standard: Personalised Information about the Risks and Benefits of Treatment Strategies for Localised Prostate Cancer.
    Eur Urol. 2018 Apr 13. pii: S0302-2838(18)30199.
    PubMed    


  431. REICHARD CA, Gregg JR, Achim MF, Aparicio AM, et al
    Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.
    Eur Urol. 2018 Apr 12. pii: S0302-2838(18)30249.
    PubMed     Abstract available


  432. ALCARAZ A, Mengual L
    Re: Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    Eur Urol. 2018 Apr 12. pii: S0302-2838(18)30256.
    PubMed    


  433. HAIDL F, Heidenreich A, Pfister D
    Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Eur Urol. 2018 Apr 10. pii: S0302-2838(18)30247.
    PubMed    


  434. VILLERS A, Olivier J
    Re: Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30242.
    PubMed    


  435. GIANNARINI G, Fossati N, Gandaglia G, Cucchiara V, et al
    Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer?
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30202.
    PubMed    


  436. MAURER T, Robu S, Schottelius M, Schwamborn K, et al
    (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30189.
    PubMed     Abstract available


  437. CARNEIRO A, Sanchez-Salas R
    Re: Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30204.
    PubMed    


  438. KAMRAN SC, Seisen T, Markt SC, Preston MA, et al
    Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cance
    Eur Urol. 2018;73:e96-e97.
    PubMed    


  439. HAJDINJAK T, Pelzer AE
    Re: What Are We Missing? False-negative Cancers at Multiparametric MR Imaging of the Prostate.
    Eur Urol. 2018;73:637.
    PubMed    


  440. FRYDENBERG M, Woo HH
    Early Androgen Deprivation Therapy Improves Survival, But How Do We Determine in Whom?
    Eur Urol. 2018;73:519-520.
    PubMed    


  441. BRAND D, Parker C
    Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation.
    Eur Urol. 2018;73:521-523.
    PubMed     Abstract available


    March 2018
  442. LAVORGNA G, Montorsi F, Salonia A
    Re: Jinjing Chen, Ilaria Guccini, Diletta Di Mitri, et al. Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer. Nat Genet 2018;50:219-28: Lipid Metabolism in Prostate Cancer: Expanding Patient Ther
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30181.
    PubMed    


  443. EKLUND M, Strom P, Nordstrom T, Gronberg H, et al
    Reply to Ola Bratt and Anna Ofverholm's Letter to the Editor re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. E
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30185.
    PubMed    


  444. TOSOIAN JJ, Lotan TL
    The Androgen Signaling Axis and Risk Stratification for High-grade Prostate Cancer.
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30188.
    PubMed    


  445. BRATT O, Ofverholm A
    Re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.0
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30186.
    PubMed    


  446. KINSELLA N, Stattin P, Cahill D, Brown C, et al
    Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30176.
    PubMed     Abstract available


  447. VAN SOEST RJ, Tombal B, Lolkema MP, de Wit R, et al
    Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?
    Eur Urol. 2018 Mar 19. pii: S0302-2838(18)30178.
    PubMed    


  448. PANEBIANCO V, Barchetti G, Simone G, Del Monte M, et al
    Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Eur Urol. 2018 Mar 19. pii: S0302-2838(18)30183.
    PubMed     Abstract available


  449. HAO J, Ci X, Xue H, Wu R, et al
    Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Mar 12. pii: S0302-2838(18)30162.
    PubMed     Abstract available


  450. MONTGOMERY B, Lin DW
    Adjuvant Chemotherapy for Prostate Cancer: The Long and Winding Road.
    Eur Urol. 2018 Mar 8. pii: S0302-2838(18)30164.
    PubMed    


  451. DAVIS ID
    Answering Questions and Questioning Answers: More Evidence To Guide Decision-making About Chemohormonal Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2018 Mar 7. pii: S0302-2838(18)30163.
    PubMed    


  452. SJOBERG DD, Vickers AJ, Assel M, Dahlin A, et al
    Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Eur Urol. 2018 Mar 5. pii: S0302-2838(18)30126.
    PubMed     Abstract available


    February 2018
  453. TYSON MD 2ND, Koyama T, Lee D, Hoffman KE, et al
    Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
    Eur Urol. 2018 Feb 28. pii: S0302-2838(18)30119.
    PubMed     Abstract available


  454. MEHRA N, Dolling D, Sumanasuriya S, Christova R, et al
    Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Eur Urol. 2018 Feb 27. pii: S0302-2838(18)30120.
    PubMed     Abstract available


  455. MAHAL BA, Yang DD, Wang NQ, Alshalalfa M, et al
    Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
    Eur Urol. 2018 Feb 22. pii: S0302-2838(18)30098.
    PubMed     Abstract available


  456. GRAVIS G, Boher JM, Chen YH, Liu G, et al
    Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Eur Urol. 2018 Feb 20. pii: S0302-2838(18)30102.
    PubMed     Abstract available


  457. CHANDRASEKAR T, Ost P, Tilki D
    Is (68)Ga-Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?
    Eur Urol. 2018 Feb 19. pii: S0302-2838(18)30083.
    PubMed    


  458. FARIA R, Soares MO, Spackman E, Ahmed HU, et al
    Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31-2.
    Eur Urol. 2018 Feb 17. pii: S0302-2838(18)30110.
    PubMed    


  459. AGGARWAL R
    Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Feb 16. pii: S0302-2838(18)30112.
    PubMed    


  460. LAMB AD, Bryant RJ, Mills IG, Hamdy FC, et al
    First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright.
    Eur Urol. 2018 Feb 16. pii: S0302-2838(18)30114.
    PubMed    


  461. MOROTE J, Comas I, Planas J
    Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration.
    Eur Urol. 2018 Feb 13. pii: S0302-2838(18)30093.
    PubMed    


  462. HAESE A
    Re: Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Eur Urol. 2018 Feb 10. pii: S0302-2838(18)30086.
    PubMed    


  463. ANTONARAKIS ES, Lu C, Luber B, Liang C, et al
    Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Eur Urol. 2018 Feb 10. pii: S0302-2838(18)30089.
    PubMed     Abstract available


  464. COOPERBERG MR, Brooks JD, Faino AV, Newcomb LF, et al
    Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Eur Urol. 2018 Feb 9. pii: S0302-2838(18)30067.
    PubMed     Abstract available


  465. FAIENA I, Salmasi A, Pantuck AJ, Drakaki A, et al
    Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    Eur Urol. 2018 Feb 9. pii: S0302-2838(18)30077.
    PubMed    


  466. AMINSHARIFI A, Polascik TJ
    Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy.
    Eur Urol. 2018 Feb 7. pii: S0302-2838(18)30076.
    PubMed    


  467. COOPERBERG MR
    How Should a Man with Prostate Cancer Choose his Surgeon?
    Eur Urol. 2018 Feb 3. pii: S0302-2838(18)30074.
    PubMed    


  468. WINTER A, Chavan A, Wawroschek F
    Magnetic Resonance Imaging of Sentinel Lymph Nodes Using Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer Patients: First-in-human Results.
    Eur Urol. 2018 Feb 2. pii: S0302-2838(18)30018.
    PubMed    


  469. TO SQ, Kwan EM, Fettke HC, Mant A, et al
    Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Feb 2. pii: S0302-2838(18)30016.
    PubMed     Abstract available


  470. PARKER C, Sydes MR
    Salvage Treatment After Radical Prostatectomy.
    Eur Urol. 2018;73:166-167.
    PubMed    


  471. CHIN JL
    Robotic-assisted Radical Prostatectomy for High-risk Cancer: Time for "Sexta-fecta".
    Eur Urol. 2018;73:224-225.
    PubMed    


  472. TILKI D, Evans CP
    The Decipher Genomic Classifier Independently Improves Prognostication for Patients After Prostatectomy.
    Eur Urol. 2018;73:176-177.
    PubMed    


  473. BRZEZNIAK C, Oronsky B, Aggarwal R
    A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.
    Eur Urol. 2018;73:306-307.
    PubMed    


  474. HERLEMANN A, Cowan JE, Carroll PR, Cooperberg MR, et al
    Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy.
    Eur Urol. 2018;73:215-223.
    PubMed     Abstract available


    January 2018
  475. TEMIZ MZ, Besiroglu H
    Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur
    Eur Urol. 2018 Jan 31. pii: S0302-2838(18)30023.
    PubMed    


  476. KAPOOR DA
    Prostate Cancer Care and Practice Patterns: Low-quality Observations Miss the Benefits from High-quality Care.
    Eur Urol. 2018 Jan 30. pii: S0302-2838(18)30006.
    PubMed    


  477. MATEO J, Cheng HH, Beltran H, Dolling D, et al
    Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
    Eur Urol. 2018 Jan 29. pii: S0302-2838(18)30019.
    PubMed     Abstract available


  478. AHLGREN GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, et al
    Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
    Eur Urol. 2018 Jan 27. pii: S0302-2838(18)30021.
    PubMed     Abstract available


  479. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical
    Eur Urol. 2018 Jan 27. pii: S0302-2838(18)30024.
    PubMed    


  480. RAUSCHER I, Duwel C, Haller B, Rischpler C, et al
    Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Eur Urol. 2018 Jan 18. pii: S0302-2838(18)30010.
    PubMed     Abstract available


  481. VAN DER POEL HG, van den Bergh RCN, Briers E, Cornford P, et al
    Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Jan 17. pii: S0302-2838(18)30005.
    PubMed     Abstract available


  482. STROM P, Nordstrom T, Gronberg H, Eklund M, et al
    The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Eur Urol. 2018 Jan 10. pii: S0302-2838(17)31096.
    PubMed     Abstract available


  483. UO T, Sprenger C
    Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward.
    Eur Urol. 2018 Jan 3. pii: S0302-2838(17)31067.
    PubMed    


  484. LEE JK, Sjoberg DD, Miller MI, Vickers AJ, et al
    Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients?
    Eur Urol. 2018;73:33-37.
    PubMed     Abstract available


  485. CULIG Z
    Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide.
    Eur Urol. 2018;73:9-10.
    PubMed    


  486. LEE B, Kim JH
    Re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e13-e14.
    PubMed    


  487. UREN AD, Cotterill N, Harding C, Hillary C, et al
    Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e15-e16.
    PubMed    


    December 2017
  488. BOSSI A
    Re: Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
    Eur Urol. 2017 Dec 26. pii: S0302-2838(17)31046.
    PubMed    


  489. FRASER M, Boutros PC, Bristow RG
    A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31021.
    PubMed    


  490. ROACH M RD
    Re: Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31041.
    PubMed    


  491. ZHANG Q, Helfand BT, Carneiro BA, Qin W, et al
    Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-beta Insensitive Genetically Targeted CD8(+) T-cells Derived from Patients with Metastatic Castrate-resistant Disease.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31040.
    PubMed     Abstract available


  492. ROCCO B, Eissa A, Bianchi G
    Re: Positron Emission Tomography/Computed Tomography-based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Dec 20. pii: S0302-2838(17)31036.
    PubMed    


  493. OZEN H, Turkeri LN
    Re: Active Surveillance in Younger Men with Prostate Cancer.
    Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31044.
    PubMed    


  494. LUO J, Attard G, Balk SP, Bevan C, et al
    Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
    Eur Urol. 2017 Dec 16. pii: S0302-2838(17)31030.
    PubMed     Abstract available


  495. ROBINSON D, Garmo H, Lissbrant IF, Widmark A, et al
    Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study.
    Eur Urol. 2017 Dec 15. pii: S0302-2838(17)31031.
    PubMed     Abstract available


  496. SPRATT DE, Dai DLY, Den RB, Troncoso P, et al
    Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
    Eur Urol. 2017 Dec 9. pii: S0302-2838(17)31016.
    PubMed     Abstract available


  497. VALE C, Fisher D, Tierney J, White I, et al
    Re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analy
    Eur Urol. 2017 Dec 9. pii: S0302-2838(17)31019.
    PubMed    


  498. WALLIS CJD, Klaassen Z
    Response to Claire Vale, David Fisher, Jayne Tierney, Ian White, Matthew Sydes, and James Carpenter's Letter to the Editor re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androge
    Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31020.
    PubMed    


  499. DONG L, Pienta KJ
    Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31023.
    PubMed    


    November 2017
  500. HAMDY FC, Lamb AD, Bryant RJ
    Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens.
    Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30994.
    PubMed    


  501. COOPERBERG MR
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30982.
    PubMed    


  502. ABDOLLAH F, Dalela D, Menon M
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Nov 22. pii: S0302-2838(17)30985.
    PubMed    


  503. LOEB S
    Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.
    Eur Urol. 2017 Nov 20. pii: S0302-2838(17)30976.
    PubMed    


  504. CRUMBAKER M, Savdie R, Joshua AM
    Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer.
    Eur Urol. 2017 Nov 18. pii: S0302-2838(17)30981.
    PubMed    


  505. MARTINI A, Gupta A, Cumarasamy S, Tewari AK, et al
    Re: Rita Faria, Marta O. Soares, Eldon Spackman, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol. In p
    Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30974.
    PubMed    


  506. LAMB AD, Bryant RJ, Camilleri P, Hamdy FC, et al
    Orient Expression: Solving the Mystery of Asian Prostate Cancer?
    Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30969.
    PubMed    


  507. LAVORGNA G, Montorsi F, Salonia A
    Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2-ERG Fusion Co-opts Master Transcription Factors and Activates NOTCH Signaling in Primary Prostate Cancer. Nat Genet 2017;49:1336-45.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30973.
    PubMed    


  508. CUCCHIARA V, Cooperberg MR, Dall'Era M, Lin DW, et al
    Genomic Markers in Prostate Cancer Decision Making.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30975.
    PubMed     Abstract available


  509. TOMBAL B
    Assembling the Puzzle of Advanced Prostate Cancer: Lessons from GETUG-AFU 15.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30968.
    PubMed    


  510. AGGARWAL R
    Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
    Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30967.
    PubMed    


  511. RAMEY SJ, Agrawal S, Abramowitz MC, Moghanaki D, et al
    Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
    Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30900.
    PubMed     Abstract available


  512. CULINE S
    Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30907.
    PubMed    


  513. IBRAGIMOVA N, Zhanzak Z, Meyerbekova A, Xie Y, et al
    Re: Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Eur Urol. 2017 Nov 4. pii: S0302-2838(17)30910.
    PubMed    


  514. MOTTET N, De Santis M, Briers E, Gillessen S, et al
    Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
    Eur Urol. 2017 Nov 2. pii: S0302-2838(17)30839.
    PubMed     Abstract available


    October 2017
  515. HEINZELBECKER J, Stockle M
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30899.
    PubMed    


  516. SPRATT DE, Dess RT, Feng FY
    Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Can
    Eur Urol. 2017 Oct 27. pii: S0302-2838(17)30897.
    PubMed    


  517. LAVAUD P, Gravis G, Foulon S, Joly F, et al
    Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naive Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Eur Urol. 2017 Oct 23. pii: S0302-2838(17)30791.
    PubMed     Abstract available


  518. ASSEL M, Dahlin A, Ulmert D, Bergh A, et al
    Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Eur Urol. 2017 Oct 21. pii: S0302-2838(17)30860.
    PubMed     Abstract available


  519. SAITO K, Fujii Y
    Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients.
    Eur Urol. 2017 Oct 20. pii: S0302-2838(17)30858.
    PubMed    


  520. GHADJAR P, Wiegel T
    Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017
    Eur Urol. 2017 Oct 19. pii: S0302-2838(17)30861.
    PubMed    


  521. GOOD DW, McNeill AS
    Re: Impact of Radical Prostatectomy on Long-term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration.
    Eur Urol. 2017 Oct 17. pii: S0302-2838(17)30844.
    PubMed    


  522. VAN DER KWAST T
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology.
    Eur Urol. 2017 Oct 14. pii: S0302-2838(17)30842.
    PubMed    


  523. TOUIJER KA, Karnes RJ, Passoni N, Sjoberg DD, et al
    Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Eur Urol. 2017 Oct 14. pii: S0302-2838(17)30828.
    PubMed     Abstract available


  524. MCLEOD DG, Petrovics G
    Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    Eur Urol. 2017 Oct 13. pii: S0302-2838(17)30845.
    PubMed    


  525. WALLIS CJD, Klaassen Z, Bhindi B, Goldberg H, et al
    Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Eur Urol. 2017 Oct 13. pii: S0302-2838(17)30849.
    PubMed     Abstract available


  526. SPAHN M
    Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    Eur Urol. 2017 Oct 12. pii: S0302-2838(17)30843.
    PubMed    


  527. PLOUSSARD G
    Re: Salvage High-intensity Focused Ultrasound (HIFU) for Locally Recurrent Prostate Cancer After Failed Radiation Therapy: Multi-institutional Analysis of 418 Patients.
    Eur Urol. 2017 Oct 12. pii: S0302-2838(17)30841.
    PubMed    


  528. VAN DEN EEDEN SK, Lu R, Zhang N, Quesenberry CP Jr, et al
    A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Eur Urol. 2017 Oct 5. pii: S0302-2838(17)30777.
    PubMed     Abstract available


    September 2017
  529. WALZ J
    The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis?
    Eur Urol. 2017 Sep 28. pii: S0302-2838(17)30779.
    PubMed    


  530. PANSADORO V, Brassetti A
    Re: Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30782.
    PubMed    


  531. CAPOGROSSO P, Montorsi F
    Erectile Function Recovery After Surgery in Young Men with Low-risk Prostate Cancer: Probably Not Just a Matter of Age, Certainly Not the Main Point of Discussion.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30726.
    PubMed    


  532. GASSER T
    Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-term Oncologic Outcomes in a Shared Equal-access Health System.
    Eur Urol. 2017 Sep 20. pii: S0302-2838(17)30727.
    PubMed    


  533. MILLER K, Carles J, Gschwend JE, Van Poppel H, et al
    The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Eur Urol. 2017 Sep 19. pii: S0302-2838(17)30728.
    PubMed     Abstract available


  534. FARIA R, Soares MO, Spackman E, Ahmed HU, et al
    Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    Eur Urol. 2017 Sep 18. pii: S0302-2838(17)30711.
    PubMed     Abstract available


  535. REN S, Wei GH, Liu D, Wang L, et al
    Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.
    Eur Urol. 2017 Sep 15. pii: S0302-2838(17)30720.
    PubMed     Abstract available


  536. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen Afte
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30719.
    PubMed    


  537. SEISEN T, Vetterlein MW, Karabon P, Jindal T, et al
    Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis.
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30697.
    PubMed     Abstract available


  538. DAL PRA A, Supiot S, Ghadjar P
    Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30718.
    PubMed    


    August 2017
  539. ZHU Y, Sharp A, Anderson CM, Silberstein JL, et al
    Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Aug 30. pii: S0302-2838(17)30695.
    PubMed     Abstract available


  540. GILLESSEN S, de Bono JS, Sartor O, Omlin AG, et al
    Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer
    Eur Urol. 2017 Aug 28. pii: S0302-2838(17)30700.
    PubMed    


  541. VON EYBEN FE, Virgolini I, Roviello G
    Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.
    Eur Urol. 2017 Aug 28. pii: S0302-2838(17)30696.
    PubMed    


  542. EGGER SJ, Calopedos RJ, O'Connell DL, Chambers SK, et al
    Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30699.
    PubMed     Abstract available


  543. TAKEDA T, Tin AL, Corradi RB, Mamoor M, et al
    Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens.
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30691.
    PubMed     Abstract available


  544. BORGMANN H, Lallous N, Ozistanbullu D, Beraldi E, et al
    Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30698.
    PubMed     Abstract available


  545. DE BONO JS, Chowdhury S, Feyerabend S, Elliott T, et al
    Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for >/=24 weeks in Europe.
    Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30664.
    PubMed     Abstract available


  546. LOEB S, Zhou Q, Siebert U, Rochau U, et al
    Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30642.
    PubMed     Abstract available


  547. HOLLENBECK BK, Kaufman SR, Yan P, Herrel LA, et al
    Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.
    Eur Urol. 2017 Aug 17. pii: S0302-2838(17)30687.
    PubMed     Abstract available


  548. SEITZ AK, Thoene S, Bietenbeck A, Nawroth R, et al
    AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Eur Urol. 2017 Aug 14. pii: S0302-2838(17)30653.
    PubMed     Abstract available


  549. WOO S, Suh CH, Kim SY
    Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cance
    Eur Urol. 2017 Aug 11. pii: S0302-2838(17)30669.
    PubMed    


  550. DEL RE M, Biasco E, Crucitta S, Derosa L, et al
    Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resi
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30663.
    PubMed    


  551. MESSINA C, Messina M, Boccardo F
    Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30659.
    PubMed    


  552. AYUBI E, Safiri S
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur Urol
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30668.
    PubMed    


  553. DE GIORGI U, Conteduca V, Scarpi E
    Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680
    Eur Urol. 2017 Aug 5. pii: S0302-2838(17)30661.
    PubMed    


  554. KLEIN EA
    Reply to Parham Habibzadeh and Farrokh Habibzadeh's Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate
    Eur Urol. 2017 Aug 5. pii: S0302-2838(17)30644.
    PubMed    


  555. DOWNER MK
    Why Epidemiological Studies of Physical Activity in Prostate Cancer Often Underestimate its Benefits.
    Eur Urol. 2017 Aug 3. pii: S0302-2838(17)30656.
    PubMed    


  556. FRIEDLANDER DF, Trinh QD, Krasnova A, Lipsitz SR, et al
    Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics.
    Eur Urol. 2017 Aug 1. pii: S0302-2838(17)30652.
    PubMed     Abstract available


    July 2017
  557. AGGARWAL R, Vigneron DB, Kurhanewicz J
    Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer.
    Eur Urol. 2017 Jul 29. pii: S0302-2838(17)30651.
    PubMed    


  558. AGGARWAL A, Lewis D, Charman SC, Mason M, et al
    Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition.
    Eur Urol. 2017 Jul 28. pii: S0302-2838(17)30601.
    PubMed     Abstract available


  559. LARDAS M, Liew M, van den Bergh RC, De Santis M, et al
    Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
    Eur Urol. 2017 Jul 27. pii: S0302-2838(17)30535.
    PubMed     Abstract available


  560. TREE A, Dearnaley D
    Randomised Controlled Trials Remain the Key to Progress in Localised Prostate Cancer.
    Eur Urol. 2017 Jul 21. pii: S0302-2838(17)30590.
    PubMed    


  561. CROOK J
    Optimal Radiotherapy for Unfavorable-risk Prostate Cancer.
    Eur Urol. 2017 Jul 21. pii: S0302-2838(17)30589.
    PubMed    


  562. PENSON DF
    Quality of Life Outcomes Following Treatment for Localized Prostate Cancer: What's New and What's Not.
    Eur Urol. 2017 Jul 20. pii: S0302-2838(17)30588.
    PubMed    


  563. CARAM MEV, Miller DC
    Treating Advanced Prostate Cancer-the Human Factor.
    Eur Urol. 2017 Jul 18. pii: S0302-2838(17)30585.
    PubMed    


  564. SPRATT DE, Dess RT, Zumsteg ZS, Lin DW, et al
    A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.
    Eur Urol. 2017 Jul 14. pii: S0302-2838(17)30527.
    PubMed     Abstract available


  565. WANG Y, Jacobs EJ, Gapstur SM, Maliniak ML, et al
    Recreational Physical Activity in Relation to Prostate Cancer-specific Mortality Among Men with Nonmetastatic Prostate Cancer.
    Eur Urol. 2017 Jul 12. pii: S0302-2838(17)30537.
    PubMed     Abstract available


  566. PARKER CC, Coleman RE, Sartor O, Vogelzang NJ, et al
    Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30516.
    PubMed     Abstract available


  567. LUO J, Luber B, Wang H, Antonarakis ES, et al
    Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection
    Eur Urol. 2017 Jul 7. pii: S0302-2838(17)30532.
    PubMed    


  568. GALFANO A, Secco S, Bocciardi AM
    Will Retzius-sparing Prostatectomy Be the Future of Prostate Cancer Surgery?
    Eur Urol. 2017 Jul 7. pii: S0302-2838(17)30523.
    PubMed    


  569. KIM JH, Lee B, Chung BI
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. ht
    Eur Urol. 2017 Jul 6. pii: S0302-2838(17)30524.
    PubMed    


  570. STEINESTEL J, Bernemann C, Schrader AJ, Lennerz JK, et al
    Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and S
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30531.
    PubMed    


  571. JOHNSON SB, Lester-Coll NH, Kelly JR, Kann BH, et al
    Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30515.
    PubMed     Abstract available


  572. WOO S, Suh CH, Kim SY
    Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30525.
    PubMed    


  573. HABIBZADEH P, Habibzadeh F
    Re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based
    Eur Urol. 2017 Jul 4. pii: S0302-2838(17)30528.
    PubMed    


    June 2017
  574. GILLESSEN S, Attard G, Beer TM, Beltran H, et al
    Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
    Eur Urol. 2017 Jun 24. pii: S0302-2838(17)30497.
    PubMed     Abstract available


  575. ALBERTS AR, Schoots IG, Bokhorst LP, Drost FH, et al
    Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic R
    Eur Urol. 2017 Jun 21. pii: S0302-2838(17)30514.
    PubMed     Abstract available


  576. D'ANDREA D, Shariat SF
    Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Jun 20. pii: S0302-2838(17)30513.
    PubMed    


  577. THYSELL E, Ylitalo EB, Jernberg E, Bergh A, et al
    Reply to Isabel Heidegger, Renate Pichler, and Andreas Pircher's Letter to the Editor re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relations
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30504.
    PubMed    


  578. TREE AC, Siva S, Ost P
    Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1-3.
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30506.
    PubMed    


  579. GANDAGLIA G, Boorjian SA, Parker WP, Zaffuto E, et al
    Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Eur Urol. 2017 Jun 13. pii: S0302-2838(17)30496.
    PubMed     Abstract available


  580. WALLIS CJD, Glaser A, Hu JC, Huland H, et al
    Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review.
    Eur Urol. 2017 Jun 10. pii: S0302-2838(17)30495.
    PubMed     Abstract available


  581. HOYLE AP, Clarke NW
    Magnetic Resonance Imaging and Detection of Metastases in Prostate Cancer: Learning Lessons from History.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30492.
    PubMed    


  582. ALBERTSEN PC
    Re: 10-Year Outcomes After Monitoring, Surgery or Radiotherapy for Localized Prostate Cancer.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30485.
    PubMed    


  583. HEIDEGGER I, Pichler R, Pircher A
    Re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017;71:776-87.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30493.
    PubMed    


  584. CLARKE NW
    Re: Nicola Fossati, Peter-Paul M. Willemse, Thomas Van den Broeck, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. In Press. http://dx.doi.org
    Eur Urol. 2017 Jun 1. pii: S0302-2838(17)30410.
    PubMed    


  585. MANDEL P, Preisser F, Graefen M, Steuber T, et al
    High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy.
    Eur Urol. 2017;71:848-850.
    PubMed     Abstract available


  586. HEESAKKERS J, Farag F, Bauer RM, Sandhu J, et al
    Pathophysiology and Contributing Factors in Postprostatectomy Incontinence: A Review.
    Eur Urol. 2017;71:936-944.
    PubMed     Abstract available


    May 2017
  587. TROCK BJ, Karnes RJ
    Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Eur Urol. 2017 May 31. pii: S0302-2838(17)30464.
    PubMed    


  588. AYUBI E, Safiri S
    Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.
    Eur Urol. 2017 May 30. pii: S0302-2838(17)30465.
    PubMed    


  589. WOO S, Suh CH, Kim SY
    Reply to Thorsten Derlin, Christoph-A. von Klot, and Katja Hueper's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Met
    Eur Urol. 2017 May 30. pii: S0302-2838(17)30470.
    PubMed    


  590. WILT TJ, Dahm P
    Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30451.
    PubMed    


  591. DERLIN T, von Klot CA, Hueper K
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. ht
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30469.
    PubMed    


  592. REICHARD CA, Chapin BF
    Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders?
    Eur Urol. 2017 May 25. pii: S0302-2838(17)30404.
    PubMed    


  593. WILT TJ, Dahm P
    Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30402.
    PubMed    


  594. COOPERBERG MR
    The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30401.
    PubMed     Abstract available


  595. WANG R, Sun Y, Li L, Niu Y, et al
    Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(R) to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30285.
    PubMed     Abstract available


  596. NGUYEN PL, Haddad Z, Ross AE, Martin NE, et al
    Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30390.
    PubMed     Abstract available


  597. HERMANNS T, Poyet C
    The Next Generation of Prostate Cancer Risk Calculators.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30387.
    PubMed    


  598. BECK M, Hayoz S, Ghadjar P
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30385.
    PubMed    


  599. HADASCHIK B, Herrmann K
    Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30388.
    PubMed    


  600. CHUA MLK, Lo W, Pintilie M, Murgic J, et al
    A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Eur Urol. 2017 May 13. pii: S0302-2838(17)30344.
    PubMed     Abstract available


  601. MITRAKAS L
    Re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol 2017;71:267-73.
    Eur Urol. 2017 May 10. pii: S0302-2838(17)30345.
    PubMed    


  602. MIRTTI T, Aittokallio T
    Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30340.
    PubMed    


  603. SEYEDNASROLLAH F, Mahmoudian M, Rautakorpi L, Hirvonen O, et al
    Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prost
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30341.
    PubMed    


  604. LEAPMAN MS, Cowan JE, Simko J, Roberge G, et al
    Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.
    Eur Urol. 2017;71:750-759.
    PubMed     Abstract available


  605. HE J, Albertsen PC, Moore D, Rotter D, et al
    Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data.
    Eur Urol. 2017;71:760-763.
    PubMed     Abstract available


  606. FROEHNER M, Koch R, Hubler M, Zastrow S, et al
    Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older.
    Eur Urol. 2017;71:710-713.
    PubMed     Abstract available


  607. BRAJTBORD JS, Leapman MS, Cooperberg MR
    The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies.
    Eur Urol. 2017;71:705-709.
    PubMed     Abstract available


  608. TOSOIAN JJ, Almutairi F, Morais CL, Glavaris S, et al
    Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
    Eur Urol. 2017;71:697-700.
    PubMed     Abstract available


  609. KISHAN AU, Shaikh T, Wang PC, Reiter RE, et al
    Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
    Eur Urol. 2017;71:766-773.
    PubMed     Abstract available


  610. STUDENT V JR, Vidlar A, Grepl M, Hartmann I, et al
    Advanced Reconstruction of Vesicourethral Support (ARVUS) during Robot-assisted Radical Prostatectomy: One-year Functional Outcomes in a Two-group Randomised Controlled Trial.
    Eur Urol. 2017;71:822-830.
    PubMed     Abstract available


    April 2017
  611. YANG JC, Evans CP
    Adjunct Screening of NKX3.1 Expression Supports 5alpha-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance.
    Eur Urol. 2017 Apr 25. pii: S0302-2838(17)30327.
    PubMed    


  612. PATEL DN, Freedland SJ
    New Prostate Cancer Biomarkers: The Search Continues.
    Eur Urol. 2017 Apr 24. pii: S0302-2838(17)30293.
    PubMed    


  613. WALSH PC
    The Search for the Missing Heritability of Prostate Cancer.
    Eur Urol. 2017 Apr 22. pii: S0302-2838(17)30283.
    PubMed     Abstract available


  614. GRUMMET JP, Plass K, N'Dow J
    Prostate Cancer Management in an Ageing Population.
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30290.
    PubMed    


  615. SOORIAKUMARAN P, Nyberg T, Akre O, Widmark A, et al
    Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
    Eur Urol. 2017 Apr 14. pii: S0302-2838(17)30282.
    PubMed     Abstract available


  616. SOOD A, Abdollah F
    Re: Diagnostic Accuracy of Multi-parametric Magnetic Resonance Imaging and Transrectal Ultrasound Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30275.
    PubMed    


  617. WOO S, Suh CH, Kim SY, Cho JY, et al
    Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30273.
    PubMed     Abstract available


  618. GANDAGLIA G, Fossati N, Zaffuto E, Bandini M, et al
    Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30280.
    PubMed     Abstract available


  619. WALKER SM, Knight LA, McCavigan AM, Logan GE, et al
    Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30238.
    PubMed     Abstract available


  620. RADTKE JP, Wiesenfarth M, Kesch C, Freitag MT, et al
    Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30267.
    PubMed     Abstract available


  621. KARNES RJ, Choeurng V, Ross AE, Schaeffer EM, et al
    Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30264.
    PubMed     Abstract available


  622. KLEIN EA, Chait A, Hafron JM, Kernen KM, et al
    The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary
    Eur Urol. 2017 Apr 7. pii: S0302-2838(17)30236.
    PubMed     Abstract available



  623. Prostate Cancer and the John West Effect.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30095.
    PubMed     Abstract available


  624. LEYH-BANNURAH SR, Gazdovich S, Budaus L, Zaffuto E, et al
    Local Therapy Improves Survival in Metastatic Prostate Cancer.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30231.
    PubMed     Abstract available


  625. DUTTA A, Panja S, Virk RK, Kim JY, et al
    Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5alpha-reductase Inhibition.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30252.
    PubMed     Abstract available


  626. WEGELIN O, van Melick HHE, Hooft L, Bosch JLHR, et al
    Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Techniqu
    Eur Urol. 2017;71:517-531.
    PubMed     Abstract available


    March 2017
  627. SCHROECK FR, Jacobs BL, Bhayani SB, Nguyen PL, et al
    Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
    Eur Urol. 2017 Mar 30. pii: S0302-2838(17)30239.
    PubMed     Abstract available


  628. KIM JH, Khandwala YS, Chung BI
    Re: Jim C. Hu, David M. Nanus, Art Sedrakyan. Increase in prostate cancer metastases at radical prostatectomy in the United States. Eur Urol 2017;71:147-9.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30234.
    PubMed    


  629. SCHWEIZER MT, Antonarakis ES, Denmeade SR
    Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30233.
    PubMed     Abstract available


  630. PORTER LH, Lawrence MG, Ilic D, Clouston D, et al
    Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    Eur Urol. 2017 Mar 22. pii: S0302-2838(17)30178.
    PubMed     Abstract available


  631. LAMB BW, Violet J, Siva S, Murphy DG, et al
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30179.
    PubMed    


  632. MOLDOVAN PC, Van den Broeck T, Sylvester R, Marconi L, et al
    What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30115.
    PubMed     Abstract available


  633. MO F, Lin D, Takhar M, Ramnarine VR, et al
    Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Eur Urol. 2017 Mar 19. pii: S0302-2838(17)30166.
    PubMed     Abstract available


  634. ALONGI F, Aiello D, Mazzola R, Cavalleri S, et al
    Re: Giorgio Gandaglia, Alberto Briganti, Noel Clarke, et al. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.01.039.
    Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30169.
    PubMed    


  635. MOSCHINI M, Carroll PR, Eggener SE, Epstein JI, et al
    Low-risk Prostate Cancer: Identification, Management, and Outcomes.
    Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30174.
    PubMed     Abstract available


  636. SMITH MR, Saad F, Rathkopf DE, Mulders PF, et al
    Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Eur Urol. 2017 Mar 14. pii: S0302-2838(17)30172.
    PubMed     Abstract available


  637. ANTONARAKIS ES
    Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer.
    Eur Urol. 2017 Mar 14. pii: S0302-2838(17)30167.
    PubMed    


  638. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    PubMed     Abstract available


  639. ADAM M, Tennstedt P, Lanwehr D, Tilki D, et al
    Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy.
    Eur Urol. 2017;71:330-336.
    PubMed     Abstract available


  640. FOSSATI N, Wiklund P, Rochat CH, Montorsi F, et al
    Robotic and Open Radical Prostatectomy: The First Prospective Randomised Controlled Trial Fuels Debate Rather than Closing the Question.
    Eur Urol. 2017;71:307-308.
    PubMed     Abstract available


  641. DASKIVICH TJ, Spiegel B, Kim HL
    Online Ratings Systems for Physicians and Institutions: Limitations of the Current State of the Art.
    Eur Urol. 2017;71:311-312.
    PubMed     Abstract available


  642. BORGHESI M, Ahmed H, Nam R, Schaeffer E, et al
    Complications After Systematic, Random, and Image-guided Prostate Biopsy.
    Eur Urol. 2017;71:353-365.
    PubMed     Abstract available


  643. MUNGOVAN SF, Sandhu JS, Akin O, Smart NA, et al
    Preoperative Membranous Urethral Length Measurement and Continence Recovery Following Radical Prostatectomy: A Systematic Review and Meta-analysis.
    Eur Urol. 2017;71:368-378.
    PubMed     Abstract available


    February 2017
  644. GRANDE P, Di Pierro GB, Mordasini L, Ferrari M, et al
    Prospective Randomized Trial Comparing Titanium Clips to Bipolar Coagulation in Sealing Lymphatic Vessels During Pelvic Lymph Node Dissection at the Time of Robot-assisted Radical Prostatectomy.
    Eur Urol. 2017;71:155-158.
    PubMed     Abstract available


  645. MA TM, Tosoian JJ, Schaeffer EM, Landis P, et al
    The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.
    Eur Urol. 2017;71:174-180.
    PubMed     Abstract available


  646. ALBERS P
    Re: Reevaluating PSA Testing Rates in the PLCO Trial.
    Eur Urol. 2017;71:300.
    PubMed    


  647. DAMSGAARD J, Joensen UN, Carlsen E, Erenpreiss J, et al
    Reply to Eugenio Ventimiglia, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Jakob Damsgaard, Ulla N. Joensen, Elisabeth Carlsen, et al. Varicocele Is Associated with Impaired Semen Quality and Reproductive Hormone Levels: A Study o
    Eur Urol. 2017;71:e71-e72.
    PubMed    


  648. STOLZENBURG JU, Kyriazis I, Liatsikos E
    Postoperative Lymphocele Formation after Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Should Not Be Considered an Inevitable Consequence of the Approach.
    Eur Urol. 2017;71:159-160.
    PubMed    


  649. PRADO K, Reiter RE
    Is Targeted Biopsy Applicable to Patients on Active Surveillance?
    Eur Urol. 2017;71:181-182.
    PubMed    


    January 2017
  650. VALERIO M, Cerantola Y, Eggener SE, Lepor H, et al
    New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.
    Eur Urol. 2017;71:17-34.
    PubMed     Abstract available


  651. SPRATT DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, et al
    Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.
    Eur Urol. 2017;71:37-43.
    PubMed     Abstract available


  652. NICITA G, Villari D, Caroassai Grisanti S, Marzocco M, et al
    Minimally Invasive Transanal Repair of Rectourethral Fistulas.
    Eur Urol. 2017;71:133-138.
    PubMed     Abstract available


  653. LI Y, Donmez N, Sahinalp C, Xie N, et al
    SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Eur Urol. 2017;71:68-78.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: